List of polymorphisms that were reviewed and indication whether they were meta-analysed with reference of the identified studies

Gene	Pathway	N of meta-anlyses	N of SNPs	SNPs	Meta-analysis	N of studies	Author	Reference
CDH1	adhesion molecules	1	2	C-160A	Yes	4 studies	Tan *et al.* 2008, Porter *et al.* 2002, Shin *et al.* 2004, Pittman *et al.* 2009,	1, 2, 3, 4,
				G-347GA	No	1 study	Shin *et al.* 2004,	3,
ICAM1	adhesion molecules	0	2	R241G	No	1 study	Theodoropoulos *et al.* 2006,	5,
				K469E	No	1 study	Theodoropoulos *et al.* 2006,	5,
MMP-1	adhesion molecules	1	1	G1607GGAAAA	Yes	5 studies	Hettiaratchi *et al.* 2007, Elander *et al.* 2006, Hinoda *et al.* 2002, Xu *et al.* 2006, Kouhkan *et al.* 2008,	6, 7, 8, 9, 10,
MMP-2	adhesion molecules	0	4	1306	No	2 studies	Hettiaratchi *et al.* 2007, Elander *et al.* 2006,	6, 7,
				790		1 study	Xu *et al.* 2007,	11,
				955		1 study	Xu *et al.* 2007,	11,
				1575		1 study	Xu *et al.* 2007,	11,
MMP-3	adhesion molecules	1	1	1612	Yes	4 studies	Hettiaratchi *et al.* 2007, Elander *et al.* 2006, Hinoda *et al.* 2002, Xu *et al.* 2006,	6, 7, 8, 9,
MMP-9	adhesion molecules	1	2	1562	Yes - from published	4 studies	Elander *et al.* 2006, Xu *et al.* 2007, Xing *et al.* 2007, McColgan *et al.* 2009,	7, 11, 12, 13,
				279	No	1 study	Xing *et al.* 2007,	12,
ADH1B	alcohol metabolism	1	3	Arg47His	Yes	5 studies	Matsuo *et al.* 2006, Yin *et al.* 2007, Landi *et al.* 2005, Gao *et al.*	14, 15, 16, 17, 18,

							2008; Yang *et al.* 2009;	
				rs2075633	No	1 study	Yang *et al.* 2009;	18;
				rs17033	No	1 study	Yang *et al.* 2009;	18;
ADH1C	alcohol metabolism	1	1	ADH3 Ile349Val	Yes	7 studies	Yin *et al.* 2007; Curtin *et al.* 2007; van der Logt *et al.* 2006; Giovannucci *et al.* 2003; Tiemersma *et al.* 2003; Homann *et al.* 2009; Chen *et al.* 2001;	15; 19; 20; 21; 22; 23; 24;
ALDH2	alcohol metabolism	1	9	Glu487Lys	Yes	8 studies	Matsuo *et al.* 2006; Kuriki *et al.* 2005; Murata *et al.* 1999; Otani *et al.* 2005; Yin *et al.* 2007; Matsuo *et al.* 2002; Gao *et al.* 2008; Yang *et al.* 2009;	14; 25; 26; 27; 15; 28; 17; 18;
				355G>A (rs886205)	No	2 studies	Landi *et al.* 2005; Yang *et al.* 2009;	16; 18;
				348T>C (rs440)	No	1 study	Landi *et al.* 2005;	16;
				52G>C (E0480_319)	No	1 study	Landi *et al.* 2005;	16;
				69G>A (E0480_302)	No	1 study	Landi *et al.* 2005;	16;
				rs4767939	No	1 study	Yang *et al.* 2009;	18;
				rs4767944	No	1 study	Yang *et al.* 2009;	18;

				rs16941669	No	1 study	Yang *et al*. 2009,	18,
				rs7296651	No	1 study	Yang *et al*. 2009,	18,
SDF1	angiogenesis	0	1	CXCL12	No	1 study	Dimberg *et al*. 2007,	29,
VEGF	angiogenesis	1	6	936C/T	Yes	4 studies	Chae *et al*. 2008,Bae *et al*. 2008,Hofmann *et al*. 2008,Wu *et al*. 2009,	30,31,32,33,
				1154G>A	No	1 study	Cacev *et al*. 2008,	34,
				460C>T	No	2 studies	Cacev *et al*. 2008,Maltese *et al*. 2009,	34,35,
				634G>C	Yes - from published	4 studies	Chae *et al*. 2008,Hofmann *et al*. 2008,Liu *et al*. 2010,	30,32,36,
				2578C>A	No	3 studies	Hofmann *et al*. 2008,Park *et al*. 2007,Maltese *et al*. 2009,	32,37,35,
				405C>G	No	1 study	Maltese *et al*. 2009,	35,
MGMT	base-excision repair	2	2	Leu84Phe	Yes - from published	5 studies	Zhong *et al*. 2010,	38,
				Ile143Val	Yes - from published	4 studies	Zhong *et al*. 2010,	38,
MUTYH	base-excision repair	2	2	G396D	Yes	12 studies	Enholm *et al*. 2003,Wang *et al*. 2004,Zhou *et al*. 2005,Peterlongo *et al*. 2005,Moreno *et al*. 2006,Schafmayer *et al*. 2007,Colebatch *et al*. 2006,Kury *et al*. 2007, Balaguer *et al*. 2007,Avezzu *et al*.	39,40,41,42,43,44,45,46,47,48,49,50

							2008, Cleary *et al*. 2009, Lubbe *et al*. 2009	
				Y179C	Yes	12 studies	Enholm *et al*. 2003, Wang *et al*. 2004, Zhou *et al*. 2005, Peterlongo *et al*. 2005, Moreno *et al*. 2006, Schafmayer *et al*. 2007, Colebatch *et al*. 2006, Kury *et al*. 2007, Balaguer *et al*. 2007, Avezzu *et al*. 2008, Cleary *et al*. 2009, Lubbe *et al*. 2009	39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
OGG1	base-excision repair	1	1	Ser326Cys	Yes	9 studies	Hansen *et al*. 2005, Moreno *et al*. 2006, Stern *et al*. 2007, Kim *et al*. 2003, Park *et al*. 2007, Sliwinski *et al*. 2009, Pardini *et al*. 2008, Curtin *et al*. 2009, Schafmayer *et al*. 2007,	51, 43, 52, 53, 54, 55, 56, 57, 44,
XRCC1	base-excision repair	3	6	Arg194Trp	Yes	10 studies	Jiang *et al*. 2010, Stern *et al*. 2007, Moreno *et al*. 2006, Hong *et al*. 2005, Gaustadnes *et al*. 2006, Curtin *et al*. 2009, Improta *et al*. 2008, Skjelbred *et al*. 2006, Stern *et al*. 2005, Berndt *et al*. 2007,	58, 52, 43, 59, 60, 57, 61, 62, 63, 64,

				Arg280His	Yes	5 studies	Moreno *et al.* 2006, Hong *et al.* 2005, Curtin *et al.* 2009, Skjelbred *et al.* 2006, Berndt *et al.* 2007,	43, 59, 57, 62, 64,
				Arg399Gln	Yes	11 studies	Jiang *et al.* 2010, Yeh *et al.* 2005, Stern *et al.* 2007, Moreno *et al.* 2006, Hong *et al.* 2005, Yeh *et al.* 2007, Curtin *et al.* 2009, Improta *et al.* 2008, Skjelbred *et al.* 2006, Stern *et al.* 2005, Berndt *et al.* 2007,	58, 65, 52, 43, 59, 66, 57, 61, 62, 63, 64,
				77T>C	No	1 study	Berndt *et al.* 2007,	64,
				IVS2+4850T>C	No	1 study	Berndt *et al.* 2007,	64,
				IVS2-216G>A	No	1 study	Berndt *et al.* 2007,	64,
XRCC3	base-excision repair	1	2	Thr241Met	Yes	9 studies	Moreno *et al.* 2006, Jiang *et al.* 2010, Yeh *et al.* 2007, Improta *et al.* 2008, Jin *et al.* 2005, Stern *et al.* 2005, Skjelbred *et al.* 2006, Tranah *et al.* 2004, Wang *et al.* 2010,	43, 58, 66, 61, 67, 63, 62, 68, 69,
				Exon 7	No	1 study	Mort *et al.* 2003,	70,
SMAD7	common low penetrance	3	33	rs4939827	Yes	12 studies	Broderick *et al.* 2007, Thompson *et al.* 2009, Pittman *et al.* 2009, Slattery *et al.* 2010, Curtin *et al.* 2009, von Holst *et al.* 2010, Xiong *et al.* 2010, Tenesa *et al.* 2008,	71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,

							Kupfer *et al.* 2010, Li *et al.* 2011, Ho *et al.* 2011,	
				rs12953717	Yes	10 studies	Broderick *et al.* 2007, Thompson *et al.* 2009, Pittman *et al.* 2009, Slattery *et al.* 2010, Curtin *et al.* 2009, Tenesa *et al.* 2008, Kupfer *et al.* 2010, Li *et al.* 2011, Ho *et al.* 2011,	71, 72, 73, 74, 75, 78, 79, 80, 81,
				rs4464148	Yes	6 studies	Broderick *et al.* 2007, Thompson *et al.* 2009, Pittman *et al.* 2009, Curtin *et al.* 2009, Li *et al.* 2011, Ho *et al.* 2011,	71, 72, 73, 75, 80, 81,
				rs2337107	No	2 studies	Slattery *et al.* 2010, Pittman *et al.* 2009,	74, 73,
				rs7238442	No	2 studies	Slattery *et al.* 2010, Pittman *et al.* 2009,	74, 73,
				rs1316447	No	1 study	Slattery *et al.* 2010,	74,
				rs3736242	No	1 study	Slattery *et al.* 2010,	74,
				rs3764482	No	1 study	Slattery *et al.* 2010,	74,
				rs12456328	No	1 study	Slattery *et al.* 2010,	74,

				rs2337106	No	1 study	Slattery *et al.* 2010[74];	
				rs4939823	No	1 study	Slattery *et al.* 2010[74];	
				rs6507874	No	1 study	Pittman *et al.* 2009[73];	
				rs6507875	No	1 study	Pittman *et al.* 2009[73];	
				rs1064040	No	1 study	Pittman *et al.* 2009[73];	
				rs8085824	No	1 study	Pittman *et al.* 2009[73];	
				Novel 1	No	1 study	Pittman *et al.* 2009[73];	
				rs34007497	No	1 study	Pittman *et al.* 2009[73];	
				rs12956924	No	1 study	Pittman *et al.* 2009[73];	
				rs4939825	No	1 study	Pittman *et al.* 2009[73];	
				rs4939567	No	1 study	Pittman *et al.* 2009[73];	
				rs4044177	No	1 study	Pittman *et al.* 2009[73];	
				rs11874392	No	1 study	Pittman *et al.* 2009[73];	
				rs4939827	No	1 study	Pittman *et al.* 2009[73];	
				rs12953717	No	1 study	Pittman *et al.* 2009[73];	

				rs7226855	No	1 study	Pittman *et al.* 2009,	73,
				rs36025258	No	1 study	Pittman *et al.* 2009,	73,
				rs9946510	No	1 study	Pittman *et al.* 2009,	73,
				rs11453375	No	1 study	Pittman *et al.* 2009,	73,
				rs6507877	No	1 study	Pittman *et al.* 2009,	73,
				rs4939829	No	1 study	Pittman *et al.* 2009,	73,
				rs12967477	No	1 study	Pittman *et al.* 2009,	73,
				rs17186877	No	1 study	Pittman *et al.* 2009,	73,
				rs12967711	No	1 study	Pittman *et al.* 2009,	73,
8q24	common low penetrance	2	13	rs6983267	Yes	19 studies	Ghoussaini *et al.* 2008, Schafmayer *et al.* 2009, Li *et al.* 2008, Matsuo *et al.* 2009, Pittman *et al.* 2008, Poynter *et al.* 2007, Curtin *et al.* 2009, Tuupanen *et al.* 2008, Tomlinson *et al.* 2007, Xiong *et al.* 2010, von Holst *et al.* 2010, Tomlinson *et al.* 2008, Haiman *et al.* 2007, Ho *et al.* 2011, Cui *et al.* 2011, Hutter *et al.* 2010,	82, 83, 84, 85, 86, 87, 75, 88, 89, 77, 76, 90, 91, 81, 92, 93, 79,

							Kupfer *et al.* 2010,	
				rs10505477	Yes	14 studies	Ghoussaini *et al.* 2008, Poynter *et al.* 2007, Curtin *et al.* 2009, Zanke *et al.* 2007, Schafmayer *et al.* 2009, Gruber *et al.* 2007, Hutter *et al.* 2010,	82, 87, 75, 94, 83, 95, 93,
				rs10090154	No	3 studies	Haiman *et al.* 2007, Matsuo *et al.* 2009, Curtin *et al.* 2009,	91, 85, 75,
				rs13254738	No	1 studies	Ghoussaini *et al.* 2008,	82,
				rs1447295	No	1 studies	Ghoussaini *et al.* 2008,	82,
				rs6983561	No	1 studies	Ghoussaini *et al.* 2008,	82,
				rs13281615	No	1 studies	Ghoussaini *et al.* 2008,	82,
				rs7000448	No	2 studies	Ghoussaini *et al.* 2008, Curtin *et al.* 2009,	82, 75,
				rs10808556	No	2 studies	Ghoussaini *et al.* 2008, Curtin *et al.* 2009,	82, 75,
				rs7014346	No	1 study	Tenesa *et al.* 2008,	78,
				rs7842552	No	1 study	Tenesa *et al.* 2008,	78,

				rs16901979	No	2 studies	Cicek *et al.* 2009,Ghoussaini *et al.* 2008,	96,82,
				rs719725	No	1 study	Zanke *et al.* 2007,	94,
				rs7013278	No	1 study	Curtin *et al.* 2009,	75,
9p24	common low penetrance	1	1	rs719725	Yes	13 studies	Zanke *et al.* 2007,Poynter *et al.* 2007,Curtin *et al.* 2009,von Holst *et al.* 2010,Kocarnik *et al.* 2010,	94,87,75,76,97,
19q13.1	common low penetrance	1	1	rs10411210	Yes	17 studies	Houlston *et al.* 2008,Kupfer *et al.* 2010,Xiong *et al.* 2010,Ho *et al.* 2011,von Holst *et al.* 2010,	98,79,77,81,76,
16q22.1	common low penetrance	1	1	rs9929218	Yes	18 studies	Houlston *et al.* 2008,Kupfer *et al.* 2010,von Holst *et al.* 2010,Xiong *et al.* 2010,Ho *et al.* 2011,Fernandez-Rozadilla *et al.* 2010,	98,79,76,77,81,99,
15q14	common low penetrance	1	1	rs4779584	Yes	9 studies	Jaeger *et al.* 2008,Kupfer *et al.* 2010,Ho *et al.* 2011,Xiong *et al.* 2010,von Holst *et al.* 2010,	100,79,81,77,76,
1q41	common low penetrance	1	1	rs6691170	Yes	11 studies	Houlston *et al.* 2010,	101,
3q26.2	common low penetrance	1	1	rs10936599	Yes	11 studies	Houlston *et al.* 2010,	101,
12q13.13	common low penetrance	1	1	rs11169552	Yes	11 studies	Houlston *et al.* 2010,	101,

20q13.33	common low penetrance	1	1	rs4925386	Yes	11 studies	Houlston *et al.* 2010[101]	
14q22.2	common low penetrance	1	1	rs4444235	Yes	13 studies	von Holst *et al.* 2010[76], Kupfer *et al.* 2010[79], Ho *et al.* 2011[81], Xiong *et al.* 2010[77], Houlston *et al.* 2008[98]	
20p12.3	common low penetrance	1	1	rs961253	Yes	13 studies	von Holst *et al.* 2010[76], Xiong *et al.* 2010[77], Ho *et al.* 2011[81], Kupfer *et al.* 2010[79], Houlston *et al.* 2008[98]	
8q23.3	common low penetrance	1	1	rs16892766	Yes	3 studies	Kupfer *et al.* 2010[79], von Holst *et al.* 2010[76]	
10p14	common low penetrance	1	1	rs10795668	Yes	6 studies	von Holst *et al.* 2010[76], Tomlinson *et al.* 2008[102], Xiong *et al.* 2010[77], Ho *et al.* 2011[81], Kupfer *et al.* 2010[79]	
11q23.1	common low penetrance	1	1	rs3802842	Yes	14 studies	Tenesa *et al.* 2008[103], Pittman *et al.* 2008[104], Xiong *et al.* 2010[77], von Holst *et al.* 2010[76], Ho *et al.* 2011[81], Kupfer *et al.* 2010[79]	
APE	DNA repair	0	1	T1349G	No	3 studies	Gu *et al.* 2009[105]	
Androgen receptor	exogenous hormones	0	1	CAGrepeat	No	1 study	Slattery *et al.* 2005[106]	
COMT	exogenous hormones	0	4	V158M	No	1 study	Landi *et al.* 2005[107]	
				186C>G	No	1 study	Landi *et al.* 2005[107]	
				H62	No	1 study	Landi *et al.* 2005[107]	

				1-98A>G	No	1 study	Landi *et al*. 2005,	107,
ERα	exogenous hormones	0	2	351A>G	No	2 studies	Slattery *et al*. 2005, Kadiyska *et al*. 2007,	106, 108,
				Pvull	No	1 study	Kadiyska *et al*. 2007,	108,
ERβ	exogenous hormones	0	2	1082G>A	No	1 study	Slattery *et al*. 2005,	106,
				CA repeat	No	1 study	Slattery *et al*. 2005,	106,
HSD17	exogenous hormones	0	0		No	0 studies		
CBS	folate/one carbon metabolism	0	1	844ins68	No	3 studies	Le Marchand *et al*. 2002, Kury *et al*. 2008, Pufulete *et al*. 2003,	109, 110, 111,
MTHFR	folate/one carbon metabolism	2	2	C677T	Yes	51 studies	Chen *et al*. 1996, Ma *et al*. 1997, Slattery *et al*. 1999, Park *et al*. 1999, Ryan *et al*. 2001, Chen *et al*. 2002, Shannon *et al*. 2002, Keku *et al*. 2002, Le Marchand *et al*. 2002, Matsuo *et al*. 2002, Sachse *et al*. 2002, Toffoli *et al*. 2003, Plaschke *et al*. 2003, Pufulete *et al*. 2003, Kim *et al*. 2004, Curtin *et al*. 2004, Yin *et al*. 2004, Ulvik *et al*. 2004, Jiang *et al*. 2005, Ulrich *et al*. 2005, Le Marchand *et al*. 2005, Otani *et al*. 2005, Matsuo *et al*. 2005, Landi *et al*. 2005, Wang *et al*.	112, 113, 114, 115, 116, 117, 118, 119, 109, 120, 121, 122, 123, 111, 124, 125, 126, 127, 128, 129, 130, 131, 132, 107, 133, 134, 135, 136, 19, 137, 138, 139, 140, 141, 142, 110, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157,

							2006; Koushik *et al*. 2006; Murtaugh *et al*. 2007; Osian *et al*. 2007; Curtin *et al*. 2007; Hubner *et al*. 2007; Zeybek *et al*. 2007; Theodoratou *et al*. 2008; Guerreiro *et al*. 2008; Lightfoot *et al*. 2008; Mokarram *et al*. 2008; Kury *et al*. 2008; Karpinski *et al*. 2010; Eussen *et al*. 2010; Naghibalhossaini *et al*. 2010; Van Guelpen *et al*. 2010; Hazra *et al*. 2010; Fernandez-Peralta *et al*. 2010; Haghighi *et al*. 2009; El Awady *et al*. 2009; de Vogel *et al*. 2009; Gallegos-Arreola *et al*. 2009; Iacopetta *et al*. 2009; Cao *et al*. 2008; Lima *et al*. 2007; Chang *et al*. 2007; Sharp *et al*. 2008;	

				A1298C	Yes	33 studies	Chen *et al*. 2002, Keku *et al*. 2002, Le Marchand *et al*. 2002, Matsuo *et al*. 2002, Toffoli *et al*. 2003, Plaschke *et al*. 2003, Pufulete *et al*. 2003, Curtin *et al*. 2004, Yin *et al*. 2004, Jiang *et al*. 2005, Ulrich *et al*. 2005, Otani *et al*. 2005, Matsuo *et al*. 2005, Landi *et al*. 2005, Wang *et al*. 2006, Koushik *et al*. 2006, Murtaugh *et al*. 2007, Osian *et al*. 2007, Curtin *et al*. 2007, Theodoratou *et al*. 2008, Lightfoot *et al*. 2008, Kury *et al*. 2008, Eussen *et al*. 2010, Naghibalhossaini *et al*. 2010, Van Guelpen *et al*. 2010, Hazra *et al*. 2010, Fernandez-Peralta *et al*. 2010, El Awady *et al*. 2009, de Vogel *et al*. 2009, Cao *et al*. 2008, Lima *et al*. 2007, Chang *et al*. 2007, Sharp *et al*. 2008,	117, 119, 109, 120, 122, 123, 111, 125, 126, 128, 129, 131, 132, 107, 133, 134, 135, 136, 19, 139, 141, 110, 144, 145, 146, 147, 148, 150, 151, 154, 155, 156, 157,

MTR	folate/one carbon metabolism	1	1	A2756G	Yes	13 studies	Steck *et al.* 2008, de Vogel *et al.* 2009, Le Marchand *et al.* 2002, Matsuo *et al.* 2002, Theodoratou *et al.* 2008, Eussen *et al.* 2010, Kury *et al.* 2008, Ulvik *et al.* 2004, Matsuo *et al.* 2005, Koushik *et al.* 2006, Curtin *et al.* 2007, Guerreiro *et al.* 2008, Kury *et al.* 2008	158, 151, 109, 120, 139, 144, 110, 127, 132, 134, 19, 140, 110
MTRR	folate/one carbon metabolism	1	6	A66G	Yes	9 studies	Steck *et al.* 2008, de Vogel *et al.* 2009, Otani *et al.* 2005, Le Marchand *et al.* 2002, Matsuo *et al.* 2002, Theodoratou *et al.* 2008, Eussen *et al.* 2010, Kury *et al.* 2008, Koushik *et al.* 2006,	158, 151, 131, 109, 120, 139, 144, 110, 134,
				Ser/Leu	No	1 study	Koushik *et al.* 2006,	134,
				Ser/Thr	No	1 study	Koushik *et al.* 2006,	134,
				Lys/Arg	No	1 study	Koushik *et al.* 2006,	134,
				Arg/Cys	No	1 study	Koushik *et al.* 2006,	134,
				His/Tyr	No	1 study	Koushik *et al.* 2006,	134,
TS	folate/one carbon metabolism	2	2	TSER	Yes	5 studies	Matsuo *et al.* 2005, Karpinski *et al.* 2010, Curtin *et al.* 2007, Ulrich *et al.*	132, 143, 159, 160, 161,

							2005; Chen *et al.* 2003;	
				Ts1494del6	Yes	4 studies	Karpinski *et al.* 2010; Curtin *et al.* 2007; Ulrich *et al.* 2005; Chen *et al.* 2003;	143, 159, 160, 161,
H-ras1	inflammation/immune response	0	1	VNTR	No	2 studies	Gosse-Brun *et al.* 1998; Vega *et al.* 2001;	162, 163,
IL-10	inflammation/immune response	1	4	1082G/A	Yes	4 studies	Cacev *et al.* 2008; Macarthur *et al.* 2005; Tsilidis *et al.* 2009; Wilkening *et al.* 2008;	164, 165, 166, 167,
				592C/A	No	3 studies	Cacev *et al.* 2008; Macarthur *et al.* 2005; Tsilidis *et al.* 2009;	164, 165, 166,
				819C/T	No	1 study	Cacev *et al.* 2008;	164,
				3584A/T	No	1 study	Hazra *et al.* 2008;	168,
IL12A	inflammation/immune response	0	4	+7506A/T	No	1 study	Landi *et al.* 2006;	169,
				+8707A/G	No	1 study	Landi *et al.* 2006;	169,
				+9177T/A	No	1 study	Landi *et al.* 2006;	169,
				+9508 G/A	No	1 study	Landi *et al.* 2006;	169,
IL18	inflammation/immune response	0	0		No	0 study		
IL-1RN	inflammation/immune response	0	1	VNTR	No	2 studies	Viet *et al.* 2005; Zumkeller *et al.* 2007;	170, 171,
IL-1β	inflammation/immune response	0	2	31T>C	No	3 studies	Zumkeller *et al.* 2007; Tsilidis *et al.*	171, 166, 165,

							2009,Macarthur *et al.* 2005,	
				511C>T	No	1 study	Zumkeller *et al.* 2007,	171,
IL-4	inflammation/immune response	0	2	588C>T	No	2 studies	Landi *et al.* 2007,Wilkening *et al.* 2008,	172,167,
				EX 1168	No	1 study	Landi *et al.* 2007,	172,
IL-6	inflammation/immune response	1	4	174G>C	Yes	8 studies	Cacev *et al.* 2010,Tsilidis *et al.* 2009,Kury *et al.* 2008,Slattery *et al.* 2007,Theodoropoulos *et al.* 2006, Landi *et al.* 2003,Vasku *et al.* 2009,Wilkening *et al.* 2008,	173,166,110,174,5, 175,176,167,
				597G>A	No	1 study	Tsilidis *et al.* 2009,	166,
				572G>C	No	2 studies	Tsilidis *et al.* 2009,Slattery *et al.* 2007,	166,174,
				596G>A	No	1 study	Vasku *et al.* 2009,	176,
IL-8	inflammation/immune response	1	1	251T/A	Yes	6 studies	Cacev *et al.* 2008,Kury *et al.* 2008,Theodoropoulos *et al.* 2006,Landi *et al.* 2003,Tsilidis *et al.* 2009, Wilkening *et al.* 2008,	164,110,5,175,166, 167,
NFKB1/ NFK1A	inflammation/immune response	0	5	intron 11	No	1 study	Landi *et al.* 2003,	175,
				94 ins/del	No	2 studies	Lewander *et al.* 2007,Riemann *et al.* 2006,	177,178,
				11306C>T	No	1 study	Hazra *et al.* 2008,	168,

				452C>G	No	1 study	Hazra *et al.* 2008,	168,
				126G>A	No	1 study	Gao *et al.* 2007,	179,
NOS2	inflammation/immune response	0	4	524T>C	No	1 study	Landi *et al.* 2006,	169,
				G954C	No	1 study	Fransen *et al.* 2005,	180,
				(TAAA)n	No	1 study	Fransen *et al.* 2005,	180,
				(CCTTT)n	No	1 study	Fransen *et al.* 2005,	180,
PPARγ	inflammation/immune response	2	4	Pro12Ala	Yes	15 studies		
				C1431T	Yes	6 studies	Siezen *et al.* 2006, Kuriki *et al.* 2006, Anderson *et al.* 2002, Kury *et al.* 2008, Vogel *et al.* 2007,	181, 182, 183, 184, 185,
				C681G	No	1 study	Koh *et al.* 2006,	186,
				C478T	No	1 study	McGreavey *et al.* 2005,	187,
PPARδ	inflammation/immune response	0	1		No	1 study	McGreavey *et al.* 2005,	187,
PTGS1/ COX1	inflammation/immune response	0	6	Trp&Arg	No	3 studies	Kury *et al.* 2008, Frank *et al.* 2010, Siezen *et al.* 2006,	110, 188, 181,
				Pro17Leu	No	1 study	Kury *et al.* 2008,	110,
				Gly213Gly	No	2 studies	Kury *et al.* 2008, Frank *et al.* 2010,	110, 188,

				Gln41Gln	No	1 study	Kury *et al.* 2008,	110,
				V444I	No	3 studies	Landi *et al.* 2006, Goodman *et al.* 2004, Siezen *et al.* 2006,	189, 190, 181,
				Leu237Met	No	2 studies	Goodman *et al.* 2004, Siezen *et al.* 2006,	190, 181,
PTGS2/ COX2	inflammation/immune response	6	19	G765C	Yes	10 studies	Cox *et al.* 2004, Thompson *et al.* 2009, Koh *et al.* 2004, Xing *et al.* 2008, Andersen *et al.* 2009, Hoff *et al.* 2009, Iglesias *et al.* 2009, Tan *et al.* 2007, Pereira *et al.* 2010, Hamajima *et al.* 2001,	191, 192, 193, 194, 195, 196, 197, 198, 199, 200,
				G306C	Yes	4 studies	Cox *et al.* 2004, Kury *et al.* 2008, Siezen *et al.* 2006, Thompson *et al.* 2009,	191, 110, 181, 192,
				C427T	Yes	6 studies	Cox *et al.* 2004, Kury *et al.* 2008, Siezen *et al.* 2006, Thompson *et al.* 2009, Andersen *et al.* 2009, Pereira *et al.* 2010,	191, 110, 181, 192, 195, 199,
				A1803G	Yes	4 studies	Cox *et al.* 2004, Kury *et al.* 2008, Siezen *et al.* 2006, Iglesias *et al.* 2009,	191, 110, 181, 197,
				V511A	Yes	4 studies	Sansbury *et al.* 2006, Lin *et al.* 2002, Goodman *et al.* 2004, Hamajima *et al.* 2001,	201, 202, 190, 200,

				A1195G	Yes	6 studies	Siezen *et al*. 2006,Thompson *et al*. 2009,Andersen *et al*. 2009,Hoff *et al*. 2009,Tan *et al*. 2007,Pereira *et al*. 2010,	181,192,195,196,198,199,
				A401G	No	1 study	Cox *et al*. 2004,	191,
				C645T	No	3 studies	Cox *et al*. 2004,Kury *et al*. 2008,Goodman *et al*. 2004,	191,110,190,
				G5209T	No	1 study	Cox *et al*. 2004,	191,
				G10335A	No	1 study	Cox *et al*. 2004,	191,
				723+38G>A	No	1 study	Thompson *et al*. 2009,	192,
				T1056C	No	1 study	Thompson *et al*. 2009,	192,
				T2427C	No	1 study	Thompson *et al*. 2009,	192,
				rs4648310	No	1 study	Thompson *et al*. 2009,	192,
				52+150T>C	No	1 study	Thompson *et al*. 2009,	192,
				A1290G	No	1 study	Tan *et al*. 2007,	198,
				C62G	No	1 study	Hamajima *et al*. 2001,	200,
				T10G	No	1 study	Hamajima *et al*. 2001,	200,

				A5720G	No	1 study	Hamajima *et al.* 2001,	200,
TLR2	inflammation/immune response	0	2	Asp299Gly	No	3 studies	Landi *et al.* 2006, Boraska Jelavic *et al.* 2006, Guo *et al.* 2006,	169, 203, 204,
				Thr399Ile	No	1 study	Boraska Jelavic *et al.* 2006,	203,
TLR4	inflammation/immune response	0	1	Arg753Gly	No	1 study	Boraska Jelavic *et al.* 2006,	203,
TNFα	inflammation/immune response	1	5	308G>A	Yes	8 studies	Wu *et al.* 2008, Park *et al.* 1998, Suchy *et al.* 2008, Theodoropoulos *et al.* 2006, Landi *et al.* 2003, Macarthur *et al.* 2005, Toth *et al.* 2007, Tsilidis *et al.* 2009,	205, 206, 207, 208, 175, 209, 210, 166,
				1031T>C	No	2 studies	Suchy *et al.* 2008, Suchy *et al.* 2008,	207, 207,
				238G>A	No	1 study	Suchy *et al.* 2008,	207,
				857C>T	No	2 studies	Suchy *et al.* 2008, Landi *et al.* 2006,	207, 211,
				863C>A	No	1 study	Suchy *et al.* 2008,	207,
TNFβ	inflammation/immune response	0	2	+50A>G	No	1 study	Hazra *et al.* 2008,	168,
				252A>G	No	2 studies	Toth *et al.* 2007, Park *et al.* 1998,	210, 206,
NOD2	inflammation/immune response	3	5	3020insC	Yes	8 studies	Alhopuro *et al.* 2004, Kurzawski *et al.* 2004, Lakatos *et al.* 2007, Papaconstantinou *et al.* 2005, Roberts *et al.*	212, 213, 214, 215, 216, 217, 218, 219,

							2006; Suchy *et al*. 2008, Tuupanen *et al*. 2007, Mockelmann *et al*. 2009;	
				G908R	Yes	5 studies	Lakatos *et al*. 2007, Papaconstantinou *et al*. 2005, Roberts *et al*. 2006, Tuupanen *et al*. 2007, Mockelmann *et al*. 2009;	214, 215, 216, 218, 219;
				R702W	Yes	5 studies	Lakatos *et al*. 2007, Papaconstantinou *et al*. 2005, Roberts *et al*. 2006, Tuupanen *et al*. 2007, Mockelmann *et al*. 2009;	214, 215, 216, 218, 219;
				C1031T	No	1 studies	Suchy *et al*. 2008;	217;
				P268S	No	1 study	Roberts *et al*. 2006;	216;
CCND1	inhibition of cell growth	1	1	870A	Yes	13 studies		
TGFB1	inhibition of cell growth	1	16	509CT	Yes - from published	5 studies	Saltzman *et al*. 2008, Amirghofran *et al*. 2009, Forsti *et al*. 2010, Fang *et al*. 2010;	220, 221, 222, 223;
				800A/G	No	2 studies	Saltzman *et al*. 2008, Amirghofran *et al*. 2009;	220, 221;
				rs1982072	No	1 study	Saltzman *et al*. 2008;	220;
				rs1982073	No	1 study	Saltzman *et al*. 2008;	220;

				rs1800471	No	1 study	Saltzman *et al*. 2008,	220,
				rs2241717	No	1 study	Saltzman *et al*. 2008,	220,
				rs4803455	No	1 study	Saltzman *et al*. 2008,	220,
				rs1549934	No	1 study	Saltzman *et al*. 2008,	220,
				rs10416269	No	1 study	Saltzman *et al*. 2008,	220,
				rs1800472	No	1 study	Saltzman *et al*. 2008,	220,
				rs2278422	No	1 study	Saltzman *et al*. 2008,	220,
				rs11466345	No	1 study	Saltzman *et al*. 2008,	220,
				rs11466349	No	1 study	Saltzman *et al*. 2008,	220,
				rs12983047	No	1 study	Saltzman *et al*. 2008,	220,
				rs6957	No	1 study	Saltzman *et al*. 2008,	220,
				rs2241718	No	1 study	Saltzman *et al*. 2008,	220,
TGFBR1	inhibition of cell growth	1	2	TGBR1*6A	Yes	8 studies	Skoglund *et al*. 2007, Forsti *et al*. 2010, Castillejo *et al*. 2009, Samowitz *et al*. 2001, Stefanovska *et al*. 2001, Pasche *et al*. 1999, Kaklamani *et al*. 2003, Pasche *et al*. 2005,	224, 222, 225, 226, 227, 228, 229, 230,

				Int7G24A	No	2 studies	Forsti *et al.* 2010, Castillejo *et al.* 2009,	222, 231,
TGFBR2	inhibition of cell growth	0	0		No	0 study		
IGF-1	insulin-related	1	5	CA-repeat	Yes	6 studies	Morimoto *et al.* 2005, Slattery *et al.* 2006, Slattery *et al.* 2004, Pechlivanis *et al.* 2007, Samowitz *et al.* 2006, Wong *et al.* 2005,	232, 233, 234, 235, 236, 237,
				rs6214	No	1 study	Feik *et al.* 2010,	238,
				rs6220	No	1 study	Feik *et al.* 2010,	238,
				1410C>T	No	2 studies	Feik *et al.* 2010, Pechlivanis *et al.* 2007,	238, 235,
				299C>A	No	1 study	Wong *et al.* 2008,	239,
				35644A>G	No	1 study	Pechlivanis *et al.* 2007,	235,
				533T>C	No	1 study	Wong *et al.* 2005,	237,
IGF-2	insulin-related	0	0		No	0 study		
IGFBP-1	insulin-related	0	1	IIe253Met	No	1 study	Pechlivanis *et al.* 2007,	240,
IGFBP-2	insulin-related	0	1		No	1 study	Hunt *et al.* 2002,	241,
IGFBP-3	insulin-related	1	4	202A>C	Yes	6 studies	Feik *et al.* 2010, Pechlivanis *et al.* 2007, Samowitz *et al.* 2006, Wong *et al.* 2005, Slattery *et al.* 2004, Slattery *et al.* 2006,	238, 235, 236, 237, 234, 233,
				Ala32Gly	No	3 studies	Feik *et al.* 2010, Morimoto *et al.* 2005, Pechlivanis *et al.* 2007,	238, 232, 235,

				806G>A	No	1 study	Pechlivanis *et al*. 2007,	235,
				A8485T	No	1 study	Pechlivanis *et al*. 2007,	235,
HFE	iron metabolism	1	3	C282T	Yes	4 studies	Shaheen *et al*. 2003, van der *et al*. 2003, Beckman *et al*. 1999, Macdonald *et al*. 1999,	242, 243, 244, 245,
				H63D	No	1 study	Shaheen *et al*. 2003,	242,
				462G>A	No	1 study	Hazra *et al*. 2008,	168,
APOE	lipid metabolism	2	2	rs429358	Yes	4 studies	Kervinen *et al*. 1996, Butler *et al*. 2001, Watson *et al*. 2003, Slattery *et al*. 2005,	246, 247, 248, 249,
				rs7412	Yes	4 studies	Kervinen *et al*. 1996, Butler *et al*. 2001, Watson *et al*. 2003, Slattery *et al*. 2005,	246, 247, 248, 249,
STK15	mitotic control	1	1	F311	Yes	4 studies	Ewart-Toland *et al*. 2005, Webb *et al*. 2006,	250, 251,
BMPR1A	rare autosomal dominant	0	0		No	0 study		
LKB1	rare autosomal dominant	0	0		No	0 study		
PTEN	rare autosomal dominant	0	4	rs926091	No	1 study	Phillips *et al*. 2009,	252,
				rs2299939	No	1 study	Phillips *et al*. 2009,	252,
				rs2248293	No	1 study	Phillips *et al*. 2009,	252,
				rs12357281	No	1 study	Phillips *et al*. 2009,	252,
SMAD4	rare autosomal dominant	0	0		No	0 study		
STK11	rare autosomal dominant	0	*0*		No	0 study		

APC	rare, high penetrance	2	6	E1317Q	Yes	6 studies	Fidder *et al*. 2005,Cleary *et al*. 2008,Theodoratou *et al*. 2008,Popat *et al*. 2000,Rozek *et al*. 2006, Hahnloser *et al*. 2003,	253,254,255,256,257, 258,
				D1822V	Yes	6 studies	Menendez *et al*. 2004,Cleary *et al*. 2008,Tranah *et al*. 2005,Theodoratou *et al*. 2008,Guerreiro *et al*. 2007,Slattery *et al*. 2001,	259,254,260,255,261, 262,
				I307K	No	3 studies	Fidder *et al*. 2005,Strul *et al*. 2003,Laken *et al*. 1997,	253,263,264,
				S130G	No	1 study	Cleary *et al*. 2008,	254,
				G2502S	No	2 studies	Cleary *et al*. 2008,Tranah *et al*. 2005,	254,260,
				rs2909962	No	1 study	Starinsky *et al*. 2005,	265,
MLH1	rare, high penetrance	2	20	93G>A	Yes	5 studies	Samowitz *et al*. 2008,Tulupova *et al*. 2008,Raptis *et al*. 2007,Koessler *et al*. 2008,Allan *et al*. 2008,	266,267,268,269,270,
				1219V	Yes	6stusdies	Raptis *et al*. 2007,Berndt *et al*. 2007,Nejda *et al*. 2009,Mei *et al*. 2006,Kim *et al*. 2004, Christensen *et al*. 2008,	268,271,272,273,274, 275,
				415G>C	No	2 studies	Tao *et al*. 2009,Nejda *et al*. 2009,	276,272,
				IVs9-1406C>T	No	1 study	Tulupova *et al*. 2008,	267,

				IVs14-19A>G	No	1 study	Raptis *et al*. 2007,	268,
				394	No	1 study	Mei *et al*. 2006,	273,
				1151	No	2 studies	Kim *et al*. 2004,Mei *et al*. 2006,	274,273,
				rs2286939	No	1 study	Koessler *et al*. 2008,	269,
				rs1800734	No	1 study	Koessler *et al*. 2008,	269,
				rs1540354	No	1 study	Koessler *et al*. 2008,	269,
				rs3774332	No	1 study	Koessler *et al*. 2008,	269,
				rs9311149	No	1 study	Koessler *et al*. 2008,	269,
				rs9852378	No	1 study	Koessler *et al*. 2008,	269,
				rs4647222	No	1 study	Koessler *et al*. 2008,	269,
				rs3774338	No	1 study	Koessler *et al*. 2008,	269,
				rs3774335	No	1 study	Koessler *et al*. 2008,	269,
				rs3774332	No	1 study	Koessler *et al*. 2008,	269,
				rs748766	No	1 study	Koessler *et al*. 2008,	269,
				rs2241031	No	1 study	Koessler *et al*. 2008;	269,

				rs10849	No	1 study	Koessler *et al.* 2008;	269;
MLH6	rare, high penetrance	0	0		No	1 study	Koessler *et al.* 2008;	269;
MSH2	rare, high penetrance	0	26	T>C Exon 13	No	1 study	Goessl *et al.* 1997;	277;
				rs17217772	No	1 study	Schafmayer *et al.* 2007;	44;
				rs17224367	No	1 study	Schafmayer *et al.* 2007;	44;
				rs7607312	No	1 study	Schafmayer *et al.* 2007;	44;
				rs10183143	No	1 study	Schafmayer *et al.* 2007;	44;
				rs17036614	No	1 study	Schafmayer *et al.* 2007;	44;
				rs2042649	No	1 study	Schafmayer *et al.* 2007;	44;
				rs6544991	No	1 study	Schafmayer *et al.* 2007;	44;
				rs6720549	No	1 study	Schafmayer *et al.* 2007;	44;
				rs1981928	No	2 studies	Schafmayer *et al.* 2007;Koessler *et al.* 2008;	44;269;
				rs3771281	No	1 study	Koessler *et al.* 2008;	269;
				rs3771274	No	1 study	Koessler *et al.* 2008;	269;
				rs2059520	No	1 study	Koessler *et al.* 2008;	269;

				rs13425206	No	1 study	Koessler *et al.* 2008[269]	
				rs4952887	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				rs13408008	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				rs17036577	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				rs4608577	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				rs4638843	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				rs1981929	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				rs6741393	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				rs1863332	No	2 studies	Schafmayer *et al.* 2007[44],Koessler *et al.* 2008[269]	
				glVS12-6	No	1 study	Kim *et al.* 2004[274]	
				1168	No	1 study	Kim *et al.* 2004[274]	
				rs2303428	No	2 studies	Tulupova *et al.* 2008[267],Koessler *et al.* 2008[269]	
				rs4987188	No	2 studies	Schafmayer *et al.* 2007[44],Tulupova *et al.* 2008[267]	
PMS1	rare, high penetrance	0	9	rs1233255	No	1 study	Koessler *et al.* 2008[269]	
				rs1233258	No	1 study	Koessler *et al.* 2008[269]	

				rs256563	No	1 study	Koessler *et al.* 2008;	269;
				rs5742981	No	1 study	Koessler *et al.* 2008;	269;
				rs7577961	No	1 study	Koessler *et al.* 2008;	269;
				rs5743116	No	1 study	Koessler *et al.* 2008;	269;
				rs5743185	No	1 study	Koessler *et al.* 2008;	269;
				rs5743047	No	1 study	Koessler *et al.* 2008;	269;
				rs17806132	No	1 study	Koessler *et al.* 2008;	269;
PMS2	rare, high penetrance		13	rs2286680	No	2 studies	Koessler *et al.* 2008, Schafmayer *et al.* 2007;	269, 44;
				rs12112229	No	2 studies	Koessler *et al.* 2008, Schafmayer *et al.* 2007;	269, 44;
				rs6463524	No	2 studies	Koessler *et al.* 2008, Schafmayer *et al.* 2007;	269, 44;
				rs2345060	No	2 studies	Koessler *et al.* 2008, Schafmayer *et al.* 2007;	269, 44;
				rs7797466	No	1 study	Koessler *et al.* 2008;	269;
				rs11769380	No	1 study	Koessler *et al.* 2008;	269;
				rs9655490	No	1 study	Koessler *et al.* 2008;	269;

				rs1805324	No	1 study	Schafmayer *et al*. 2007,	44,
				rs1805318	No	1 study	Schafmayer *et al*. 2007,	44,
				rs12534423	No	1 study	Schafmayer *et al*. 2007,	44,
				rs18053220	No	1 study	Schafmayer *et al*. 2007,	44,
				rs13245536	No	1 study	Schafmayer *et al*. 2007,	44,
				rs2009115	No	1 study	Schafmayer *et al*. 2007,	44,
MSH6	rare, high penetrance	0	21	556G>T (rs3136228)	No	1 study	Tulupova *et al*. 2008,	267,
				145G>A (rs1042821)	No	3 studies	Tulupova *et al*. 2008, Campbell *et al*. 2009, Curtin *et al*. 2009,	267, 278, 279,
				101G>C (2072447)	No	2 studies	Tulupova *et al*. 2008, Koessler *et al*. 2008,	267, 269,
				rs3136245	No	2 studies	Schafmayer *et al*. 2007, Koessler *et al*. 2008,	44, 269,
				rs1800935	No	2 studies	Schafmayer *et al*. 2007, Koessler *et al*. 2008,	44, 269,
				rs3136326	No	2 studies	Schafmayer *et al*. 2007, Koessler *et al*. 2008,	44, 269,
				rs3136329	No	2 studies	Schafmayer *et al*. 2007, Koessler *et al*. 2008,	44, 269,
				rs1800936	No	2 studies	Schafmayer *et al*. 2007, Koessler *et al*. 2008,	44, 269,

				rs2020911	No	2 studies	Schafmayer *et al.* 2007,Koessler *et al.* 2008,	44,269,
				rs6713506	No	2 studies	Schafmayer *et al.* 2007,Koessler *et al.* 2008,	44,269,
				rs2537742	No	2 studies	Schafmayer *et al.* 2007,Koessler *et al.* 2008,	44,269,
				rs3136247	No	1 study	Schafmayer *et al.* 2007,	44,
				rs3136284	No	1 study	Schafmayer *et al.* 2007,	44,
				rs2020908	No	1 study	Schafmayer *et al.* 2007,	44,
				rs3136334	No	1 study	Schafmayer *et al.* 2007,	44,
				rs2020912	No	1 study	Schafmayer *et al.* 2007,	44,
				rs2020914	No	1 study	Schafmayer *et al.* 2007,	44,
				rs3136337	No	1 study	Schafmayer *et al.* 2007,	44,
				rs330792	No	1 study	Koessler *et al.* 2008,	269,
				rs1800932	No	1 study	Koessler *et al.* 2008,	269,
				rs2348244	No	1 study	Koessler *et al.* 2008,	269,
CYP1A1	substrate metabolism	2	9	3698T>C	Yes	7 studies	Nisa *et al.* 2010,Little *et al.* 2006,Chen *et al.* 2005,Slattery *et al.* 2004,Cotterchio *et al.* 2008, Landi *et al.* 2005,Sachse	280,281,282,283,284, 107,121,

							et al. 2002;	
				2454A>G	Yes	11 studies	Nisa *et al.* 2010; Little *et al.* 2006; Slattery *et al.* 2004; Kiss *et al.* 2000; Yeh *et al.* 2007; Cotterchio *et al.* 2008; Kobayashi *et al.* 2009; Pereira Serafim *et al.* 2008; Kiss *et al.* 2007; Landi *et al.* 2005; Sachse *et al.* 2002;	280; 281; 283; 285; 66; 284; 286; 287; 288; 107; 121;
				m4	No	1 study	Little *et al.* 2006;	281;
				3FR	No	1 study	Butler *et al.* 2001;	247;
				3229G>A	No	1 study	Landi *et al.* 2005;	107;
				3219C>T	No	1 study	Landi *et al.* 2005;	107;
				1734A>C	No	1 study	Landi *et al.* 2005;	107;
				rs4134577	No	1 study	Landi *et al.* 2005;	107;
				R464S	No	1 study	Landi *et al.* 2005;	107;
CYP11A1	substrate metabolism	0	1	3188G>A	No	1 study	Bethke *et al.* 2007;	289;
CYP17A1	substrate metabolism	0	1	34T>C	No	1 study	Bethke *et al.* 2007;	289;
CYP19A1	substrate metabolism	0	2	*19C>T	No	1 study	Bethke *et al.* 2007;	289;

				14872T>C		1 study	Hazra *et al.* 2008,	168,
CYP1A2	substrate metabolism	1	8	163C>A	Yes	9 studies	Cotterchio *et al.* 2008,Kobayashi *et al.* 2009, Saebo *et al.* 2008,Kury *et al.* 2007, Bae *et al.* 2006,Landi *et al.* 2005,Sachse *et al.* 2002,Kiss *et al.* 2007,Chen *et al.* 2005,	284,286,290,291,292,107,121,288,293,
				CYP1A2*1C	No	1 study	Yeh *et al.* 2007,	66,
				29351T>C	No	1 study	Bethke *et al.* 2007,	289,
				1548T>C	No	2 studies	Kury *et al.* 2007, Landi *et al.* 2005,	107, 291,
				3860G>A	No	1 study	Bae *et al.* 2006,	292,
				3858G>A	No	2 studies	Landi *et al.* 2005,Sachse *et al.* 2002,	107,121,
				740G>T	No	1 study	Landi *et al.* 2005,	107,
				2464delT	No	1 study	Sachse *et al.* 2002,	121,
CYP1B1	substrate metabolism	1	7	4326C>G	Yes	5 studies	Cotterchio *et al.* 2008,Bethke *et al.* 2007,Kury *et al.* 2007,Landi *et al.* 2005,Sachse *et al.* 2002,	284,289,291,107,121,
				142C>G	No	2 studies	Cotterchio *et al.* 2008,Landi *et al.* 2005,	284,107,

				4390A>G	No	3 studies	Cotterchio *et al.* 2008, Bethke *et al.* 2007, Landi *et al.* 2005,	284, 289, 107,
				5781C>T	No	1 study	Bethke *et al.* 2007,	289,
				4793C>T	No	1 study	Bethke *et al.* 2007,	289,
				4245A>G	No	1 study	Bethke *et al.* 2007,	289,
				3592G>C	No	1 study	Bethke *et al.* 2007,	289,
CYP2C19	substrate metabolism	0	2	681G>A (*2)	No	3 studies	Tamer *et al.* 2006, Landi *et al.* 2005, Sachse *et al.* 2002,	294, 107, 121,
				*3	No	1 study	Tamer *et al.* 2006,	294,
CYP2C8	substrate metabolism	0	1		No	1 study	McGreavey *et al.* 2005,	187,
CYP2C9	substrate metabolism	2	3	430C>T	Yes	5 studies	Cotterchio *et al.* 2008, McGreavey *et al.* 2005, Kury *et al.* 2007, Landi *et al.* 2005, Martinez *et al.* 2001,	284, 187, 291, 107, 295,
				1057A>C	No	5 studies	Cotterchio *et al.* 2008, McGreavey *et al.* 2005, Liao *et al.* 2007, Landi *et al.* 2005, Martinez *et al.* 2001,	284, 187, 296, 107, 295,
				1425A>T	No	1 study	Liao *et al.* 2007,	296,
CYP2D6	substrate metabolism	0	9	V11M	No	1 study	Landi *et al.* 2005,	107,

				P34S	No	1 study	Landi *et al*. 2005,	107,
				L91M	No	1 study	Landi *et al*. 2005,	107,
				T98	No	1 study	Landi *et al*. 2005,	107,
				V136	No	1 study	Landi *et al*. 2005,	107,
				1846G>A	No	2 studies	Landi *et al*. 2005, Sachse *et al*. 2002,	107, 121,
				R296C	No	1 study	Landi *et al*. 2005,	107,
				S486T	No	1 study	Landi *et al*. 2005,	107,
				2549A>del	No	1 study	Sachse *et al*. 2002,	121,
CYP2E1	substrate metabolism	2	11	1293G>C	Yes	7 studies	Kiss *et al*. 2000, Cotterchio *et al*. 2008, Yu *et al*. 2004, Kury *et al*. 2007, Landi *et al*. 2005, Kiss *et al*. 2007, Chen *et al*. 2005,	285, 284, 297, 291, 107, 288, 293,
				1053C>T	Yes	7 studies	Morita *et al*. 2009, Gao *et al*. 2007, van der Logt *et al*. 2006, Le Marchand *et al*. 2002, Kury *et al*. 2007, Landi *et al*. 2005, Chen *et al*. 2005,	298, 299, 20, 300, 291, 107, 293,
				5FR	No	1 study	Butler *et al*. 2001,	247,
				Intron 6	No	2 studies	Butler *et al*. 2001, van der Logt *et al*. 2006,	247, 20,
				7362T>A	No	1 study	Cotterchio *et al*. 2008,	284,

				rs1329149	No	1 study	Yang *et al*. 2009	18
				96-bp insertion	No	1 study	Morita *et al*. 2009	298
				insert	No	1 study	Le Marchand *et al*. 2002	300
				TaqL	No	1 study	Landi *et al*. 2005	107
				333T>A	No	1 study	Landi *et al*. 2005	107
				71G>T	No	1 study	Landi *et al*. 2005	107
CYP3A4	substrate metabolism	0	7	1334T>C	No	1 study	Bethke *et al*. 2007	289
				20230G>A	No	2 studies	Bethke *et al*. 2007, Landi *et al*. 2005	289, 107
				151751T>G	No	1 study	Bethke *et al*. 2007	289
				Arg162Gln	No	1 study	Bethke *et al*. 2007	289
				62C>A	No	1 study	Bethke *et al*. 2007	289
				4713G>A	No	1 study	Bethke *et al*. 2007	289
				4358C>G	No	1 study	Bethke *et al*. 2007	289
CYP3A5	substrate metabolism	0	3	2125T>C	No	2 studies	Petrova *et al*. 2007, Bethke *et al*. 2007	301, 289
				rs49785886	No	2 studies	Petrova *et al*. 2007, Bethke *et al*. 2007	301, 289

				12083G>A	No	2 studies	Petrova *et al*. 2007,Bethke *et al*. 2007,	301,289,
CYP7A1	substrate metabolism	0	1		No	1 study	Hagiwara *et al*. 2005,	302,
GSTA1	substrate metabolism	1	1	GSTA1*B	Yes -from published	4 studies	Sweeney *et al*. 2002,Kury *et al*. 2008,Martinez *et al*. 2006,van der Logt *et al*. 2004, Economopoulos *et al*. 2010,	303,110,304,305, 306,
GSTM1	substrate metabolism	1	1	GSTM1 deletion	Yes	43 studies	Nisa *et al*. 2010,Yeh *et al*. 2010,Yang *et al*. 2010,Piao *et al*. 2009,Epplein *et al*. 2009, Probst-Hensch *et al*. 2006,Landi *et al*. 2005,Ates *et al*. 2005,Yeh *et al*. 2005,van der Logt *et al*. 2004, Sachse *et al*. 2002,Loktionov *et al*. 2001,Huang *et al*. 2006,Little *et al*. 2006,Fan *et al*. 2006, Nascimento *et al*. 2003,Zhu *et al*. 2002,Butler *et al*. 2001,Gertig *et al*. 1998,Skjelbred *et al*. 2007, Tiemersma *et al*. 2002,Kiss *et al*. 2000,Zhong *et al*. 1993, Kampman *et al*. 1999,Slattery *et al*. 2000,Seow *et al*. 2002,	280,307,308,309,310, 311,107,312,313,305, 121,314,315,281,316, 317,318,247,319,320, 321,285,322,323,324,325 ,326,327,328,329,330,66 ,331,332,284,333,110,33 4,335,336,337,304,338,

							Deakin *et al*. 1996, van der Hel *et al*. 2003, Kiss *et al*. 2004, Chenevix-Trench *et al*. 1995, Lee *et al*. 1998, Yeh *et al*. 2007, Yoshioka *et al*. 1999, Matakova *et al*. 2009, Cotterchio *et al*. 2008, Slattery *et al*. 2003, Kury *et al*. 2008, Welfare *et al*. 1999, Csejtei *et al*. 2008, Sgambato *et al*. 2002, Laso *et al*. 2002, Martinez *et al*. 2006, Katoh *et al*. 1996,	
GSTP1	substrate metabolism	2	2	II105Val	Yes	21 studies	Yeh *et al*. 2010, Epplein *et al*. 2009, Martinez *et al*. 2006, Probst-Hensch *et al*. 2006, Sun *et al*. 2005, Landi *et al*. 2005, Ates *et al*. 2005, Yeh *et al*. 2005, Kiss *et al*. 2004, van der Logt *et al*. 2004, Sachse *et al*. 2002, Loktionov *et al*. 2001, Yoshioka *et al*. 1999, Harris *et al*. 1998, Skjelbred *et al*. 2007, Seow *et al*. 2002, Yeh *et al*. 2007, Katoh *et al*. 1999, Kury *et al*. 2008, Matakova	307, 310, 304, 311, 339, 107, 312, 313, 328, 305, 121, 314, 331, 340, 320, 325, 66, 341, 110, 332, 334,

							et al. 2009,Welfare *et al.* 1999,	
				Ala114Val	Yes	4 studies	Landi *et al.* 2005,Sachse *et al.* 2002,Harris *et al.* 1998,Kury *et al.* 2008,	107,121,340,110,
GSTT1	substrate metabolism	1	1	GSTT1 deletion	Yes	35 studies	Nisa *et al.* 2010,Yeh *et al.* 2010,Yang *et al.* 2010,Piao *et al.* 2009,Matakova *et al.* 2009, Csejtei *et al.* 2008,Epplein *et al.* 2009,Probst-Hensch *et al.* 2006,Ates *et al.* 2005,Yeh *et al.* 2005, van der Logt *et al.* 2004,Sachse *et al.* 2002,Loktionov *et al.* 2001,Fan *et al.* 2006,Huang *et al.* 2006 ,Little *et al.* 2006,Nascimento *et al.* 2003, Laso *et al.* 2002,Zhu *et al.* 2002,Butler *et al.* 2001, Gertig *et al.* 1998,Skjelbred *et al.* 2007,Seow *et al.*	280,307,308,309,332,335,310,311,312,313,305,121,314,316,315,281,317,337,318,247,319,320,325,326,327,328,329,66,304,110,284,342,334,331,338,

							2002,Deakin *et al.* 1996,van der Hel *et al.* 2003, ,Kiss *et al.* 2004,Chenevix-Trench *et al.* 1995,Yeh *et al.* 2007,Martinez *et al.* 2006,Kury *et al.* 2008,Cotterchio *et al.* 2008,Rajagopal *et al.* 2005,Welfare *et al.* 1999,Yoshioka *et al.* 1999,Katoh *et al.* 1996,	
NAT1	substrate metabolism	1	7	slow/fast	Yes	15 studies	Butler *et al.* 2001,van der Hel *et al.* 2003,Kiss *et al.* 2004,Yeh *et al.* 2007,Katoh *et al.* 2000,Yoshioka *et al.* 1999,Chen *et al.* 1998,Jass *et al.* 1995,Mahid *et al.* 2007,Roemer *et al.* 2008,Butler *et al.* 2008, Lilla *et al.* 2006,Le Marchand *et al.* 2001,Tiemersma *et al.* 2002,Sorensen *et al.* 2008	247,327,328,66,343,331, 344,345,346,347,348, 349,350,321,351
				459G>A	No	2 studies	Cotterchio *et al.* 2008,Landi *et al.* 2005,	284,107,
				1088T>A	No	2 studies	Cotterchio *et al.* 2008,Landi *et al.* 2005,	284,107,

				344C>T	No	1 study	Landi *et al.* 2005,	107,
				40A>T	No	1 study	Landi *et al.* 2005,	107,
				V149I	No	1 study	Landi *et al.* 2005,	107,
				R187Stop	No	1 study	Landi *et al.* 2005,	107,
				R187Q	No	1 study	Landi *et al.* 2005,	107,
NAT2	substrate metabolism	1	10	slow/fast	Yes	26 studies	Butler *et al.* 2001, Kiss *et al.* 2004, Slattery *et al.* 1998, Yeh *et al.* 2007, Slattery *et al.* 2000, Katoh *et al.* 2000, Yoshioka *et al.* 1999, Hubbard *et al.* 1997, Lee *et al.* 1998, Chen *et al.* 1998, Gil *et al.* 1998, Sorensen *et al.* 2008, Huang *et al.* 2007, Slattery *et al.* 2003, Mahid *et al.* 2007, Lilla *et al.* 2006, Chan *et al.* 2005, Sachse *et al.* 2002, Le Marchand *et al.* 2001, Agundez *et al.* 2000, Kampman *et al.* 1999, Kobayashi *et al.* 2009, Tiemersma *et al.* 2002, Bell *et al.* 1995, Butler *et al.* 2008, Shibuta *et al.* 1994,	247, 328, 352, 66, 324, 343, 331, 353, 354, 344, 355, 351, 356, 333, 346, 349, 357, 121, 350, 358, 323, 286, 321, 359, 348, 360,

				341T>C	No	1 study	Cotterchio *et al*. 2008,	284,
				590G>A	No	1 study	Cotterchio *et al*. 2008,	284,
				857G>A	No	1 study	Cotterchio *et al*. 2008,	284,
				R64Q	No	1 study	Landi *et al*. 2005,	107,
				282C>T	No	1 study	Landi *et al*. 2005,	107,
				I114T	No	1 study	Landi *et al*. 2005,	107,
				R197Q	No	1 study	Landi *et al*. 2005,	107,
				L268R	No	1 study	Landi *et al*. 2005,	107,
				G286E	No	1 study	Landi *et al*. 2005,	107,
				481C>T	No	1 study	Landi *et al*. 2005,	107,
NQ01	substrate metabolism	1	1	Pro187Ser (609C>T)	Yes	7 studies	Hamajima *et al*. 2002, Harth *et al*. 1999, Sachse *et al*. 2002, Van Der Logt *et al*. 2005, Lafuente *et al*. 2000, Begleiter *et al*. 2006, Mitrou *et al*. 2002,	361, 362, 363, 364, 365, 366, 367,
TP53	tumour supressor genes	2	2	Arg72Pro	From published	27 studies	Economopoulos *et al*. 2010,	368,
				intron 3 16bp del	From published	5 studies	Hu *et al*. 2010,	369,

MDM2	tumour supressor genes	1	1	309GT	Yes -from published	7 studies	Fang *et al*. 2010[370].	
VDR	vit D and Ca metabolism	3	8	FokI (27823C>T)	Yes	8 studies	Flugge *et al*. 2007[371], Jenab *et al*. 2009[372], Li *et al*. 2009[373], Murtaugh *et al*. 2006[374], Ochs-Balcom *et al*. 2008[375], Theodoratou *et al*. 2008[376], Park *et al*. 2006[377], Wong *et al*. 2003[378].	
				BsmI (60890G>A)	Yes	7 studies	Flugge *et al*. 2007[371], Jenab *et al*. 2009[372], Kadiyska *et al*. 2007[108], Li *et al*. 2009[373], Park *et al*. 2006[377], Slattery *et al*. 2004[379], Theodoratou *et al*. 2008[376].	
				TaqI (61968T>C)	Yes	4 studies	Flugge *et al*. 2007[371], Ochs-Balcom *et al*. 2008[375], Park *et al*. 2006[377], Slatter *et al*. 2001[380].	
				Poly (A)	No	2 studies	Flugge *et al*. 2009[381], Slattery *et al*. 2004[379].	
				61050G>A	No	1 study	Flugge *et al*. 2007[371].	
				61888G>T	No	3 studies	Flugge *et al*. 2007[371], Park *et al*. 2006[377], Theodoratou *et al*. 2008[376].	
				29648A>G	No	1 study	Theodoratou *et al*. 2008[376].	
				23005G>A	No	2 studies	Flugge *et al*. 2007[371], Ochs-Balcom *et al*. 2008[375].	

References

1. Tan, X. L. *et al*. The association of cyclin D1 G870A and E-cadherin C-160A polymorphisms with the risk of colorectal cancer in a case control study and meta-analysis. *Int. J. Cancer* **122**, 2573-2580 (2008).

2. Porter, T. R. *et al*. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. *Oncogene* **21**, 1928-1933 (2002).

3. Shin, Y. *et al*. A functional polymorphism (-347 G-->GA) in the E-cadherin gene is associated with colorectal cancer. *Carcinogenesis* **25**, 2173-2176 (2004).

4. Pittman, A. M. *et al*. The CDH1-160C>A polymorphism is a risk factor for colorectal cancer. *Int. J. Cancer* **125**, 1622-1625 (2009).

5. Theodoropoulos, G. *et al*. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. *World J. Gastroenterol.* **12**, 5037-5043 (2006).

6. Hettiaratchi, A. *et al*. The collagenase-1 (MMP-1) gene promoter polymorphism -1607/2G is associated with favourable prognosis in patients with colorectal cancer. *Br. J. Cancer* **96**, 783-792 (2007).

7. Elander, N., Soderkvist, P. & Fransen, K. Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. *Anticancer Res.* **26**, 791-795 (2006).

8. Hinoda, Y. *et al*. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. *Int. J. Cancer* **102**, 526-529 (2002).

9. Xu, E., Lai, M., Lu, B., Xing, X. & Huang, Q. No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese. *Dis. Colon Rectum* **49**, 1439-1444 (2006).

10. Kouhkan, F., Motovali-Bashi, M. & Hojati, Z. The influence of interstitial collagenase-1 genotype polymorphism on colorectal cancer risk in Iranian population. *Cancer Invest.* **26**, 836-842 (2008).

11. Xu, E. *et al*. Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. *Mol. Carcinog.* **46**, 924-929 (2007).

12. Xing, L. L. *et al*. Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. *World J. Gastroenterol.* **13**, 4626-4629 (2007).

13. McColgan, P. & Sharma, P. Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. *Int. J. Cancer* **125**, 1473-1478 (2009).

14. Matsuo, K. *et al*. A gene-gene interaction between ALDH2 Glu487Lys and ADH2 His47Arg polymorphisms regarding the risk of colorectal cancer in Japan. *Carcinogenesis* **27**, 1018-1023 (2006).

15. Yin, G. *et al*. Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. *Cancer. Sci.* **98**, 1248-1253 (2007).

16. Landi, S. *et al*. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. *Pharmacogenet Genomics* **15**, 535-546 (2005).

17. Gao, C. M. *et al*. Polymorphisms of alcohol dehydrogenase 2 and aldehyde dehydrogenase 2 and colorectal cancer risk in Chinese males. *World J. Gastroenterol.* **14**, 5078-5083 (2008).

18. Yang, H. *et al*. A novel polymorphism rs1329149 of CYP2E1 and a known polymorphism rs671 of ALDH2 of alcohol metabolizing enzymes are associated with colorectal cancer in a southwestern Chinese population. *Cancer Epidemiol. Biomarkers Prev.* **18**, 2522-2527 (2009).

19. Curtin, K. *et al*. Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. *Carcinogenesis* **28**, 1672-1679 (2007).

20. van der Logt, E. M. *et al*. Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. *Mutat. Res.* **593**, 39-49 (2006).

21. Giovannucci, E. *et al*. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. *Cancer Epidemiol. Biomarkers Prev.* **12**, 970-979 (2003).

22. Tiemersma, E. W. *et al*. Alcohol consumption, alcohol dehydrogenase 3 polymorphism, and colorectal adenomas. *Cancer Epidemiol. Biomarkers Prev.* **12**, 419-425 (2003).

23. Homann, N. *et al*. Alcohol and colorectal cancer: the role of alcohol dehydrogenase 1C polymorphism. *Alcohol. Clin. Exp. Res.* **33**, 551-556 (2009).

24. Chen, J. *et al*. Alcohol dehydrogenase 3 genotype is not predictive for risk of colorectal cancer. *Cancer Epidemiology, Biomarkers & Prevention* **10**, 1303-1304 (2001).

25. Kuriki, K. *et al*. Relation of the CD36 gene A52C polymorphism to the risk of colorectal cancer among Japanese, with reference to with the aldehyde dehydrogenase

2 gene Glu487Lys polymorphism and drinking habit. *Asian Pac. J. Cancer. Prev.* **6**, 62-68 (2005).

26. Murata, M. *et al*. Genotype difference of aldehyde dehydrogenase 2 gene in alcohol drinkers influences the incidence of Japanese colorectal cancer patients. *Jap. J. Cancer Res.* **90**, 711-719 (1999).

27. Otani, T. *et al*. Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital-based case-control study in Japan. *Nutr. Cancer* **53**, 42-50 (2005).

28. Matsuo, K. *et al*. Aldehyde dehydrogenase 2 (ALDH2) genotype affects rectal cancer susceptibility due to alcohol consumption. *J. Epidemiol.* **12**, 70-76 (2002).

29. Dimberg, J., Hugander, A., Lofgren, S. & Wagsater, D. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. *Int. J. Mol. Med.* **19**, 11-15 (2007).

30. Chae, Y. S. *et al*. Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer. *J. Korean Med. Sci.* **23**, 421-427 (2008).

31. Bae, S. J. *et al*. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C>T) gene and colon cancer in Korea. *Anticancer Res.* **28**, 1271-1276 (2008).

32. Hofmann, G. *et al*. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. *J. Cancer Res. Clin. Oncol.* **134**, 591-595 (2008).

33. Wu, G. Y. *et al*. Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. *World J. Surg.* **33**, 124-129 (2009).

34. Cacev, T., Loncar, B., Seiwerth, S., Spaventi, S. & Kapitanovic, S. Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. *DNA Cell Biol.* **27**, 569-574 (2008).

35. Maltese, P. *et al*. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. *Int. J. Colorectal Dis.* **24**, 165-170 (2009).

36. Liu, L. *et al*. Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies. *J. Cancer Res. Clin. Oncol.* (2010).

37. Park, H. M. *et al*. Gender-specific association of the VEGF -2578C > A polymorphism in Korean patients with colon cancer. *Anticancer Res.* **27**, 2535-2539 (2007).

38. Zhong, Y. *et al*. Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis. *Mutagenesis* **25**, 83-95 (2010).

39. Enholm, S. *et al*. Proportion and phenotype of MYH-associated colorectal neoplasia in a population-based series of Finnish colorectal cancer patients. *Am. J. Pathol.* **163**, 827-832 (2003).

40. Wang, L. *et al*. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. *Gastroenterology* **127**, 9-16 (2004).

41. Zhou, X. L. *et al*. Germline mutations in the MYH gene in Swedish familial and sporadic colorectal cancer. *Genet. Test.* **9**, 147-151 (2005).

42. Peterlongo, P. *et al*. Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. *International Journal of Cancer* **114**, 505-507 (2005).

43. Moreno, V. *et al*. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. *Clin. Cancer Res.* **12**, 2101-2108 (2006).

44. Schafmayer, C. *et al*. Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer. *Int. J. Cancer* **121**, 555-558 (2007).

45. Colebatch, A. *et al*. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. *Br. J. Cancer* **95**, 1239-1243 (2006).

46. Kury, S. *et al*. The thorough screening of the MUTYH gene in a large French cohort of sporadic colorectal cancers. *Genet. Test.* **11**, 373-379 (2007).

47. Balaguer, F. *et al*. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin. Gastroenterol. Hepatol.* **5**, 379-387 (2007).

48. Avezzu, A. *et al*. The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. *Cancer Lett.* **268**, 308-313 (2008).

49. Cleary, S. P. *et al*. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. *Gastroenterology* **136**, 1251-1260 (2009).

50. Lubbe, S. J., Di Bernardo, M. C., Chandler, I. P. & Houlston, R. S. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. *J. Clin. Oncol.* **27**, 3975-3980 (2009).

51. Hansen, R. *et al*. GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. *Cancer Lett.* **229**, 85-91 (2005).

52. Stern, M. C. *et al*. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. *Cancer Epidemiol. Biomarkers Prev.* **16**, 2363-2372 (2007).

53. Kim, J. I. *et al*. hOGG1 Ser326Cys polymorphism modifies the significance of the environmental risk factor for colon cancer. *World J. Gastroenterol.* **9**, 956-960 (2003).

54. Park, H. W. *et al*. The hOGG1 Ser326Cys polymorphism is not associated with colorectal cancer risk. *J. Epidemiol.* **17**, 156-160 (2007).

55. Sliwinski, T. *et al*. Common polymorphisms in the XPD and hOGG1 genes are not associated with the risk of colorectal cancer in a Polish population. *Tohoku J. Exp. Med.* **218**, 185-191 (2009).

56. Pardini, B. *et al*. DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic. *Mutat. Res.* **638**, 146-153 (2008).

57. Curtin, K. *et al*. Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. *Cancer Epidemiol. Biomarkers Prev.* **18**, 3384-3388 (2009).

58. Jiang, Z., Li, C., Xu, Y. & Cai, S. A meta-analysis on XRCC1 and XRCC3 polymorphisms and colorectal cancer risk. *Int. J. Colorectal Dis.* **25**, 169-180 (2010).

59. Hong, Y. C. *et al*. Polymorphisms of XRCC1 gene, alcohol consumption and colorectal cancer. *Int. J. Cancer* **116**, 428-432 (2005).

60. Gaustadnes, M., Orntoft, T. F., Jensen, J. L. & Torring, N. Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs. *Hum. Mutat.* **27**, 187-194 (2006).

61. Improta, G. *et al*. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population. *Anticancer Res.* **28**, 2941-2946 (2008).

62. Skjelbred, C. F. *et al*. Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. *BMC Cancer* **6**, 67 (2006).

63. Stern, M. C., Siegmund, K. D., Corral, R. & Haile, R. W. XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. *Cancer Epidemiol. Biomarkers Prev.* **14**, 609-615 (2005).

64. Berndt, S. I. *et al*. Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. *Cancer Res.* **67**, 1395-1404 (2007).

65. Yeh, C. C., Sung, F. C., Tang, R., Chang-Chieh, C. R. & Hsieh, L. L. Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan. *BMC Cancer* **5**, 12 (2005).

66. Yeh, C. C., Sung, F. C., Tang, R., Chang-Chieh, C. R. & Hsieh, L. L. Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. *J. Biomed. Sci.* **14**, 183-193 (2007).

67. Jin, M. J. *et al*. The association of the DNA repair gene XRCC3 Thr241Met polymorphism with susceptibility to colorectal cancer in a Chinese population. *Cancer Genet. Cytogenet.* **163**, 38-43 (2005).

68. Tranah, G. J. *et al*. XRCC2 and XRCC3 polymorphisms are not associated with risk of colorectal adenoma. *Cancer Epidemiol. Biomarkers Prev.* **13**, 1090-1091 (2004).

69. Wang, J. *et al*. Polymorphisms in DNA repair genes XRCC1, XRCC3 and XPD, and colorectal cancer risk: a case-control study in an Indian population. *J. Cancer Res. Clin. Oncol.* **136**, 1517-1525 (2010).

70. Mort, R., Mo, L., McEwan, C. & Melton, D. W. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. *Br. J. Cancer* **89**, 333-337 (2003).

71. Broderick, P. *et al*. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. *Nat. Genet.* **39**, 1315-1317 (2007).

72. Thompson, C. L. *et al*. Association of common genetic variants in SMAD7 and risk of colon cancer. *Carcinogenesis* **30**, 982-986 (2009).

73. Pittman, A. M. *et al*. The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. *Genome Res.* **19**, 987-993 (2009).

74. Slattery, M. L. *et al*. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. *Cancer Res.* **70**, 1479-1485 (2010).

75. Curtin, K. *et al*. Meta association of colorectal cancer confirms risk alleles at 8q24 and 18q21. *Cancer Epidemiol. Biomarkers Prev.* **18**, 616-621 (2009).

76. von Holst, S. *et al*. Association studies on 11 published colorectal cancer risk loci. *Br. J. Cancer* **103**, 575-580 (2010).

77. Xiong, F. *et al*. Risk of genome-wide association study-identified genetic variants for colorectal cancer in a Chinese population. *Cancer Epidemiol. Biomarkers Prev.* **19**, 1855-1861 (2010).

78. Tenesa, A. *et al*. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat. Genet.* **40**, 631-637 (2008).

79. Kupfer, S. S. *et al*. Genetic heterogeneity in colorectal cancer associations between African and European americans. *Gastroenterology* **139**, 1677-85, 1685.e1-8 (2010).

80. Li, X. *et al*. A risk-associated single nucleotide polymorphism of SMAD7 is common to colorectal, gastric, and lung cancers in a Han Chinese population. *Mol. Biol. Rep.* (2011).

81. Ho, J. W. *et al*. Replication study of SNP associations for colorectal cancer in Hong Kong Chinese. *Br. J. Cancer* **104**, 369-375 (2011).

82. Ghoussaini, M. *et al*. Multiple loci with different cancer specificities within the 8q24 gene desert. *J. Natl. Cancer Inst.* **100**, 962-966 (2008).

83. Schafmayer, C. *et al*. Investigation of the colorectal cancer susceptibility region on chromosome 8q24.21 in a large German case-control sample. *Int. J. Cancer* **124**, 75-80 (2009).

84. Li, L. *et al*. A common 8q24 variant and the risk of colon cancer: a population-based case-control study. *Cancer Epidemiol. Biomarkers Prev.* **17**, 339-342 (2008).

85. Matsuo, K. *et al*. Association between an 8q24 locus and the risk of colorectal cancer in Japanese. *BMC Cancer* **9**, 379 (2009).

86. Pittman, A. M. *et al*. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. *Br. J. Cancer* **98**, 1434-1436 (2008).

87. Poynter, J. N. *et al*. Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. *Cancer Res.* **67**, 11128-11132 (2007).

88. Tuupanen, S. *et al*. Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. *Cancer Res.* **68**, 14-17 (2008).

89. Tomlinson, I. *et al*. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. *Nat. Genet.* **39**, 984-988 (2007).

90. Tomlinson, I. P. *et al*. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. *Nat. Genet.* **40**, 623-630 (2008).

91. Haiman, C. A. *et al*. A common genetic risk factor for colorectal and prostate cancer. *Nat. Genet.* **39**, 954-956 (2007).

92. Cui, R. *et al*. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. *Gut* (2011).

93. Hutter, C. M. *et al*. Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis. *BMC Cancer* **10**, 670 (2010).

94. Zanke, B. W. *et al*. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. *Nat. Genet.* **39**, 989-994 (2007).

95. Gruber, S. B. *et al*. Genetic variation in 8q24 associated with risk of colorectal cancer. *Cancer. Biol. Ther.* **6**, 1143-1147 (2007).

96. Cicek, M. S. *et al*. Functional and clinical significance of variants localized to 8q24 in colon cancer. *Cancer Epidemiol. Biomarkers Prev.* **18**, 2492-2500 (2009).

97. Kocarnik, J. D. *et al*. Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis. *Cancer Epidemiol. Biomarkers Prev.* **19**, 3131-3139 (2010).

98. Houlston, R. S. *et al*. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. *Nat. Genet.* **40**, 1426-1435 (2008).

99. Fernandez-Rozadilla, C. *et al*. Single nucleotide polymorphisms in the Wnt and BMP pathways and colorectal cancer risk in a Spanish cohort. *PLoS One* **5**, e12673 (2010).

100. Jaeger, E. *et al*. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. *Nat. Genet.* **40**, 26-28 (2008).

101. Houlston, R. S. *et al*. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. *Nat. Genet.* **42**, 973-977 (2010).

102. Tomlinson, I. P. *et al*. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. *Nat. Genet.* (2008).

103. Tenesa, A. *et al*. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat. Genet.* (2008).

104. Pittman, A. M. *et al*. Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. *Hum. Mol. Genet.* **17**, 3720-3727 (2008).

105. Gu, D., Wang, M., Wang, M., Zhang, Z. & Chen, J. The DNA repair gene APE1 T1349G polymorphism and cancer risk: a meta-analysis of 27 case-control studies. *Mutagenesis* **24**, 507-512 (2009).

106. Slattery, M. L. *et al*. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. *Cancer Epidemiology, Biomarkers & Prevention* **14**, 2936-2942 (2005).

107. Landi, S. *et al*. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. *Pharmacogenetics & Genomics* **15**, 535-546 (2005).

108. Kadiyska, T. *et al*. Vitamin D and estrogen receptor gene polymorphisms and the risk of colorectal cancer in Bulgaria. *Int. J. Colorectal Dis.* **22**, 395-400 (2007).

109. Le Marchand, L. *et al*. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). *Cancer Causes Control* **13**, 239-248 (2002).

110. Kury, S. *et al*. Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. *BMC Cancer* **8**, 326 (2008).

111. Pufulete, M. *et al*. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. *Gastroenterology* **124**, 1240-1248 (2003).

112. Chen, J. *et al*. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. *Cancer Res.* **56**, 4862-4864 (1996).

113. Ma, J. *et al*. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. *Cancer Res.* **57**, 1098-1102 (1997).

114. Slattery, M. L., Potter, J. D., Samowitz, W., Schaffer, D. & Leppert, M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. *Cancer Epidemiol Biomarkers Prev* **8**, 513-518 (1999).

115. Park, K. S., Mok, J. W. & Kim, J. C. The 677>T mutation in 5,10-Methylenetetrahydrofolate reductase and colorectal cancer risk. *Genet. Test.* **3**, 233-236 (1999).

116. Ryan, B. M. *et al*. The methylenetetrahydrofolate reductase (MTHFR) gene in colorectal cancer: role in tumor development and significance of allelic loss in tumor progression. *International Journal of Gastrointestinal Cancer* **30**, 105-111 (2001).

117. Chen, J. *et al*. Linkage disequilibrium between the 677C>T and 1298A>C polymorphisms in human methylenetetrahydrofolate reductase gene and their contributions to risk of colorectal cancer. *Pharmacogenetics* **12**, 339-342 (2002).

118. Shannon, B., Gnanasampanthan, S., Beilby, J. & Iacopetta, B. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. *Gut* **50**, 520-524 (2002).

119. Keku, T. *et al*. 5,10-methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. *Cancer Epidemiol Biomarkers Prev* **11**, 1611-1621 (2002).

120. Matsuo, K. *et al*. Methionine Synthase Reductase Gene A66G Polymorphism is Associated with Risk of Colorectal Cancer. *Asian Pac. J. Cancer. Prev.* **3**, 353-359 (2002).

121. Sachse, C. *et al*. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. *Carcinogenesis* **23**, 1839-1849 (2002).

122. Toffoli, G. *et al*. Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in North Italy. *Clin. Cancer Res.* **9**, 743-748 (2003).

123. Plaschke, J., Schwanebeck, U., Pistorius, S., Saeger, H. D. & Schackert, H. K. Methylenetetrahydrofolate reductase polymorphisms and risk of sporadic and hereditary colorectal cancer with or without microsatellite instability. *Cancer Lett* **191**, 179-185 (2003).

124. Kim, D. *et al*. Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. *Cancer Letters* **216**, 199-205 (2004).

125. Curtin, K. *et al*. MTHFR *C677T* and *A1298C* polymorphisms: diet, estrogen and risk of colon cancer. *Cancer Epidemiology Biomarkers & Prevention* **13**, 285-292 (2004).

126. Yin, G. *et al*. *Methylenetetrahydrofolate reductase C677T* and *A1298C* polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. *Cancer Science* **95**, 908-913 (2004).

127. Ulvik, A. *et al*. Colorectal cancer and the methylenetetrahydrofolate reductase 677C -> T and methionine synthase 2756A -> G polymorphisms: a study of 2,168 case-control pairs from the JANUS cohort. *Cancer Epidemiol. Biomarkers Prev.* **13**, 2175-2180 (2004).

128. Jiang, Q. *et al*. Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. *Cancer Detect. Prev.* **29**, 146-154 (2005).

129. Ulrich, C. M. *et al*. MTHFR variants reduce the risk of G:C->A:T transition mutations within the p53 tumor suppressor gene in colon tumors. *J. Nutr.* **135**, 2462-2467 (2005).

130. Le Marchand, L., Wilkens, L. R., Kolonel, L. N. & Henderson, B. E. The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. *Cancer Epidemiology, Biomarkers & Prevention* **14**, 1198-1203 (2005).

131. Otani, T. *et al*. Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital-based case-control study in Japan. *Nutrition & Cancer* **53**, 42-50 (2005).

132. Matsuo, K. *et al*. One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. *Carcinogenesis* **26**, 2164-2171 (2005).

133. Wang, J. *et al*. Associations between 5,10-methylenetetrahydrofolate reductase codon 677 and 1298 genetic polymorphisms and environmental factors with reference to susceptibility to colorectal cancer: a case-control study in an Indian population. *International Journal of Cancer* **118**, 991-997 (2006).

134. Koushik, A. *et al*. Nonsynonymous polymorphisms in genes in the one-carbon metabolism pathway and associations with colorectal cancer. *Cancer Epidemiology, Biomarkers & Prevention* **15**, 2408-2417 (2006).

135. Murtaugh, M. A. *et al*. Dietary intake of folate and co-factors in folate metabolism, MTHFR polymorphisms, and reduced rectal cancer. *Cancer Causes Control* **18**, 153-163 (2007).

136. Osian, G., Procopciuc, L. & Vlad, L. MTHFR polymorphisms as prognostic factors in sporadic colorectal cancer. *J. Gastrointestin Liver Dis.* **16**, 251-256 (2007).

137. Hubner, R. A., Lubbe, S., Chandler, I. & Houlston, R. S. MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer. *Hum. Mol. Genet.* **16**, 1072-1077 (2007).

138. Zeybek, U. *et al*. Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer. *Cell Biochem. Funct.* **25**, 419-422 (2007).

139. Theodoratou, E. *et al*. Dietary vitamin b6 intake and the risk of colorectal cancer. *Cancer Epidemiol. Biomarkers Prev.* **17**, 171-182 (2008).

140. Guerreiro, C. S. *et al*. Risk of colorectal cancer associated with the C677T polymorphism in 5,10-methylenetetrahydrofolate reductase in Portuguese patients depends on the intake of methyl-donor nutrients. *Am. J. Clin. Nutr.* **88**, 1413-1418 (2008).

141. Lightfoot, T. J. *et al*. Methylene tetrahydrofolate reductase genotype modifies the chemopreventive effect of folate in colorectal adenoma, but not colorectal cancer. *Cancer Epidemiol. Biomarkers Prev.* **17**, 2421-2430 (2008).

142. Mokarram, P. *et al*. Methylenetetrahydrofolate reductase C677T genotype affects promoter methylation of tumor-specific genes in sporadic colorectal cancer through an interaction with folate/vitamin B12 status. *World J. Gastroenterol.* **14**, 3662-3671 (2008).

143. Karpinski, P. *et al*. Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype. *Cancer. Epidemiol.* (2010).

144. Eussen, S. J. *et al*. Plasma folate, related genetic variants, and colorectal cancer risk in EPIC. *Cancer Epidemiol. Biomarkers Prev.* **19**, 1328-1340 (2010).

145. Naghibalhossaini, F. *et al*. MTHFR C677T and A1298C variant genotypes and the risk of microsatellite instability among Iranian colorectal cancer patients. *Cancer Genet. Cytogenet.* **197**, 142-151 (2010).

146. Van Guelpen, B. *et al*. One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. *Cancer Causes Control* **21**, 557-566 (2010).

147. Hazra, A. *et al*. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. *Cancer Causes Control* **21**, 331-345 (2010).

148. Fernandez-Peralta, A. M. *et al*. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. *Int. J. Colorectal Dis.* **25**, 141-151 (2010).

149. Haghighi, M. M. *et al*. Association between MTHFR polymorphism (C677T) with nonfamilial colorectal cancer. *Oncol. Res.* **18**, 57-63 (2009).

150. El Awady, M. K. *et al*. Methylenetetrahydrofolate reductase gene polymorphisms and the risk of colorectal carcinoma in a sample of Egyptian individuals. *Cancer. Biomark* **5**, 233-240 (2009).

151. de Vogel, S. *et al*. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. *Cancer Epidemiol. Biomarkers Prev.* **18**, 3086-3096 (2009).

152. Gallegos-Arreola, M. P. *et al*. Association of the 677C -->T polymorphism in the MTHFR gene with colorectal cancer in Mexican patients. *Cancer. Genomics Proteomics* **6**, 183-188 (2009).

153. Iacopetta, B. *et al*. The MTHFR C677T and DeltaDNMT3B C-149T polymorphisms confer different risks for right- and left-sided colorectal cancer. *Int. J. Cancer* **125**, 84-90 (2009).

154. Cao, H. X. *et al*. Genetic polymorphisms of methylenetetrahydrofolate reductase and susceptibility to colorectal cancer. *Asian Pac. J. Cancer. Prev.* **9**, 203-208 (2008).

155. Lima, C. S. *et al*. Polymorphisms in methylenetetrahydrofolate reductase gene (MTHFR) and the age of onset of sporadic colorectal adenocarcinoma. *Int. J. Colorectal Dis.* **22**, 757-763 (2007).

156. Chang, S. C. *et al*. Role of MTHFR polymorphisms and folate levels in different phenotypes of sporadic colorectal cancers. *Int. J. Colorectal Dis.* **22**, 483-489 (2007).

157. Sharp, L. *et al*. Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intake. *Br. J. Nutr.* **99**, 379-389 (2008).

158. Steck, S. E. *et al*. Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyltransferase, folate and alcohol intake, and colon cancer risk. *J. Nutrigenet Nutrigenomics* **1**, 196-204 (2008).

159. Curtin, K. *et al*. Thymidylate synthase polymorphisms and colon cancer: associations with tumor stage, tumor characteristics and survival. *Int. J. Cancer* **120**, 2226-2232 (2007).

160. Ulrich, C. M. *et al*. Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. *Cancer Epidemiol. Biomarkers Prev.* **14**, 2509-2516 (2005).

161. Chen, J. *et al*. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. *Cancer Epidemiology, Biomarkers & Prevention* **12**, 958-962 (2003).

162. Gosse-Brun, S. *et al*. Association between H-ras minisatellite and colorectal cancer risk. *Anticancer Res.* **18**, 2611-2616 (1998).

163. Vega, A., Barros, F., Lleonart, M. E., Ramon y Cajal, S. & Carracedo, A. HRAS1 minisatellite alleles in colorectal carcinoma: relationship to microsatelite instability. *Anticancer Res.* **21**, 2855-2860 (2001).

164. Cacev, T., Radosevic, S., Krizanac, S. & Kapitanovic, S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. *Carcinogenesis* **29**, 1572-1580 (2008).

165. Macarthur, M., Sharp, L., Hold, G. L., Little, J. & El-Omar, E. M. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. *Cancer Epidemiol. Biomarkers Prev.* **14**, 1613-1618 (2005).

166. Tsilidis, K. K. *et al*. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. *Cancer Causes Control* **20**, 1739-1751 (2009).

167. Wilkening, S. *et al*. Interleukin promoter polymorphisms and prognosis in colorectal cancer. *Carcinogenesis* **29**, 1202-1206 (2008).

168. Hazra, A. *et al*. Large-scale evaluation of genetic variants in candidate genes for colorectal cancer risk in the Nurses' Health Study and the Health Professionals' Follow-up Study. *Cancer Epidemiol. Biomarkers Prev.* **17**, 311-319 (2008).

169. Landi, S. *et al*. Polymorphisms within inflammatory genes and colorectal cancer. *J. Negat Results Biomed.* **5**, 15 (2006).

170. Viet, H. T., Wagsater, D., Hugander, A. & Dimberg, J. Interleukin-1 receptor antagonist gene polymorphism in human colorectal cancer. *Oncol. Rep.* **14**, 915-918 (2005).

171. Zumkeller, N. *et al*. Helicobacter pylori infection, interleukin-1 gene polymorphisms and the risk of colorectal cancer: evidence from a case-control study in Germany. *Eur. J. Cancer* **43**, 1283-1289 (2007).

172. Landi, S. *et al*. Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. *Eur. J. Cancer* **43**, 762-768 (2007).

173. Cacev, T., Jokic, M., Loncar, B., Krizanac, S. & Kapitanovic, S. Interleukin-6-174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. *DNA Cell Biol.* **29**, 177-182 (2010).

174. Slattery, M. L., Wolff, R. K., Herrick, J. S., Caan, B. J. & Potter, J. D. IL6 genotypes and colon and rectal cancer. *Cancer Causes & Control* **18**, 1095-1105 (2007).

175. Landi, S. *et al*. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. *Cancer Res.* **63**, 3560-3566 (2003).

176. Vasku, A., Vokurka, J. & Bienertova-Vasku, J. Obesity-related genes variability in Czech patients with sporadic colorectal cancer: preliminary results. *Int. J. Colorectal Dis.* **24**, 289-294 (2009).

177. Lewander, A. *et al*. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. *Scand. J. Gastroenterol.* **42**, 1332-1338 (2007).

178. Riemann, K. *et al*. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. *Pharmacogenet Genomics* **16**, 783-788 (2006).

179. Gao, J. *et al*. Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. *Scand. J. Gastroenterol.* **42**, 345-350 (2007).

180. Fransen, K., Elander, N. & Soderkvist, P. Nitric oxide synthase 2 (NOS2) promoter polymorphisms in colorectal cancer. *Cancer Lett.* **225**, 99-103 (2005).

181. Siezen, C. L. *et al*. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. *International Journal of Cancer* **119**, 297-303 (2006).

182. Kuriki, K. *et al*. Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese. *Cancer Science* **97**, 1226-1235 (2006).

183. Anderson, W. F. *et al*. Colorectal cancer screening for persons at average risk. *J Natl Cancer Inst* **94**, 1126-1133 (2002).

184. Kury, S. *et al*. Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study. *BMC Cancer* **8**, 326 (2008).

185. Vogel, U. *et al*. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. *Mutat. Res.* **624**, 88-100 (2007).

186. Koh, W. P., Yuan, J. M., Van Den Berg, D., Ingles, S. A. & Yu, M. C. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and

colorectal cancer risk among Chinese in Singapore. *Carcinogenesis* **27**, 1797-1802 (2006).

187. McGreavey, L. E. *et al*. No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. *Pharmacogenet Genomics* **15**, 713-721 (2005).

188. Frank, B. *et al*. Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk. *Int. J. Cancer* (2010).

189. Landi, S. *et al*. Polymorphisms within inflammatory genes and colorectal cancer. *Journal of Negative Results in Biomedicine* **5**, 15 (2006).

190. Goodman, J. E., Bowman, E. D., Chanock, S. J., Alberg, A. J. & Harris, C. C. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. *Carcinogenesis* **25**, 2467-2472 (2004).

191. Cox, D. G. *et al*. Polymorphisms in prostaglandin synthase2/cyclooxygenase 2 (*PTGS2/COX2*) and risk of colorectal cancer. *British Journal of Cancer* **91**, 339-343 (2004).

192. Thompson, C. L. *et al*. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. *World J. Gastroenterol.* **15**, 2240-2244 (2009).

193. Koh, W., Yuan, J., van der Berg, D., Lee, H. & Yu, M. C. Interaction between *cyclooxygenase-2* gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study. *British Journal of Cancer* **90**, 1760-1764 (2004).

194. Xing, L. L. *et al*. Cyclooxygenase 2 polymorphism and colorectal cancer: -765G>C variant modifies risk associated with smoking and body mass index. *World J. Gastroenterol.* **14**, 1785-1789 (2008).

195. Andersen, V. *et al*. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. *BMC Cancer* **9**, 407 (2009).

196. Hoff, J. H. *et al*. COX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer risk. *World J. Gastroenterol.* **15**, 4561-4565 (2009).

197. Iglesias, D. *et al*. Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. *Cancer Causes Control* **20**, 1421-1429 (2009).

198. Tan, W. *et al*. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. *Carcinogenesis* **28**, 1197-1201 (2007).

199. Pereira, C. *et al*. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. *Eur. J. Gastroenterol. Hepatol.* **22**, 607-613 (2010).

200. Hamajima, N. *et al*. Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer. *Asian Pac. J. Cancer. Prev.* **2**, 57-62 (2001).

201. Sansbury, L. B. *et al*. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). *Cancer Causes & Control* **17**, 257-266 (2006).

202. Lin, H. J. *et al*. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. *Cancer Epidemiol Biomarkers Prev* **11**, 1305-1315 (2002).

203. Boraska Jelavic, T. *et al*. Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. *Clin. Genet.* **70**, 156-160 (2006).

204. Guo, Q., Zhu, J. & Xia, B. Polymorphism of CD14 gene but not the mutation of TLR4 gene is associated with colorectal cancer in Chinese patients. *J. Gastroenterol. Hepatol.* **21**, 92-97 (2006).

205. Wu, G. Y., Wang, X. M., Keese, M., Hasenberg, T. & Sturm, J. W. [Association between tumor necrosis factor alpha gene polymorphism and colorectal cancer]. *Zhonghua Wei Chang Wai Ke Za Zhi* **11**, 569-571 (2008).

206. Park, K. S., Mok, J. W., Rho, S. A. & Kim, J. C. Analysis of TNFB and TNFA NcoI RFLP in colorectal cancer. *Mol. Cells* **8**, 246-249 (1998).

207. Suchy, J. *et al*. Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. *BMC Cancer* **8**, 112 (2008).

208. Theodoropoulos, G. *et al*. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. *World J. Gastroenterol.* **12**, 5037-5043 (2006).

209. Macarthur, M., Sharp, L., Hold, G. L., Little, J. & El-Omar, E. M. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. *Cancer Epidemiol. Biomarkers Prev.* **14**, 1613-1618 (2005).

210. Toth, E. K. *et al*. The 8.1 ancestral MHC haplotype is strongly associated with colorectal cancer risk. *Int. J. Cancer* **121**, 1744-1748 (2007).

211. Landi, S. *et al*. Polymorphisms within inflammatory genes and colorectal cancer. *J. Negat Results Biomed.* **5**, 15 (2006).

212. Alhopuro, P. *et al*. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. *Cancer Res.* **64**, 7245-7247 (2004).

213. Kurzawski, G. *et al*. The NOD2 3020insC mutation and the risk of colorectal cancer. *Cancer Res.* **64**, 1604-1606 (2004).

214. Lakatos, P. L. *et al*. Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. *BMC Cancer* **7**, 54 (2007).

215. Papaconstantinou, I. *et al*. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. *Int. J. Cancer* **114**, 433-435 (2005).

216. Roberts, R. L. *et al*. Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. *Cancer Res.* **66**, 2532-2535 (2006).

217. Suchy, J. *et al*. Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. *BMC Cancer* **8**, 112 (2008).

218. Tuupanen, S., Alhopuro, P., Mecklin, J. P., Jarvinen, H. & Aaltonen, L. A. No evidence for association of NOD2 R702W and G908R with colorectal cancer. *International Journal of Cancer* **121**, 76-79 (2007).

219. Mockelmann, N. *et al*. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. *BMC Gastroenterol.* **9**, 79 (2009).

220. Saltzman, B. S. *et al*. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. *Cancer Res.* **68**, 1236-1244 (2008).

221. Amirghofran, Z., Jalali, S. A., Ghaderi, A. & Hosseini, S. V. Genetic polymorphism in the transforming growth factor beta1 gene (-509 C/T and -800 G/A) and colorectal cancer. *Cancer Genet. Cytogenet.* **190**, 21-25 (2009).

222. Forsti, A. *et al*. Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression. *Genes Chromosomes Cancer* **49**, 270-281 (2010).

223. Fang, F., Yu, L., Zhong, Y. & Yao, L. TGFB1 509 C/T polymorphism and colorectal cancer risk: a meta-analysis. *Med. Oncol.* **27**, 1324-1328 (2010).

224. Skoglund, J. *et al*. Lack of an association between the TGFBR1*6A variant and colorectal cancer risk. *Clin. Cancer Res.* **13**, 3748-3752 (2007).

225. Castillejo, A. *et al*. The TGFBR1*6A allele is not associated with susceptibility to colorectal cancer in a Spanish population: a case-control study. *BMC Cancer* **9**, 193 (2009).

226. Samowitz, W. S., Curtin, K., Leppert, M. F. & Slattery, M. L. Uncommon TGFBRI allele is not associated with increased susceptibility to colon cancer. *Genes Chromosomes Cancer* **32**, 381-383 (2001).

227. Stefanovska, A. M. *et al*. TbetaR-I(6A) polymorphism is not a tumor susceptibility allele in Macedonian colorectal cancer patients. Correspondence re: B. Pasche et al. Type I TbetaR-I(6A) Is a Candidate Tumor Susceptibility Allele. Cancer Res., 58: 2727-2732, 1998. *Cancer Res.* **61**, 8351-8352 (2001).

228. Pasche, B. *et al*. TbetaR-I(6A) is a candidate tumor susceptibility allele. *Cancer Res.* **59**, 5678-5682 (1999).

229. Kaklamani, V. G. *et al*. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. *Journal of Clinical Oncology* **21**, 3236-3243 (2003).

230. Pasche, B. *et al*. Somatic acquisition and signaling of TGFBR1*6A in cancer. *JAMA* **294**, 1634-1646 (2005).

231. Castillejo, A. *et al*. The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study. *BMC Cancer* **9**, 406 (2009).

232. Morimoto, L. M., Newcomb, P. A., White, E., Bigler, J. & Potter, J. D. Insulin-like growth factor polymorphisms and colorectal cancer risk. *Cancer Epidemiol. Biomarkers Prev.* **14**, 1204-1211 (2005).

233. Slattery, M. L. *et al*. PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). *Cancer Causes & Control* **17**, 239-249 (2006).

234. Slattery, M. L. *et al*. Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. *Cancer Epidemiology, Biomarkers & Prevention* **13**, 1206-1214 (2004).

235. Pechlivanis, S. *et al*. Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer. *Cancer Detect. Prev.* **31**, 408-416 (2007).

236. Samowitz, W. S. *et al*. Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. *Mutat. Res.* **595**, 117-124 (2006).

237. Wong, H. L. *et al*. A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in singapore chinese. *Cancer Epidemiol. Biomarkers Prev.* **14**, 144-151 (2005).

238. Feik, E. *et al*. Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. *Cancer Causes Control* **21**, 91-97 (2010).

239. Wong, H. L. *et al*. Insulin-like growth factor-1 promoter polymorphisms and colorectal cancer: a functional genomics approach. *Gut* **57**, 1090-1096 (2008).

240. Pechlivanis, S. *et al*. Insulin pathway related genes and risk of colorectal cancer: INSR promoter polymorphism shows a protective effect. *Endocr. Relat. Cancer* **14**, 733-740 (2007).

241. Hunt, K. J. *et al*. Insulin-like growth factor II and colorectal cancer risk in women. *Cancer Epidemiology, Biomarkers & Prevention* **11**, 901-905 (2002).

242. Shaheen, N. J. *et al*. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. *J. Natl. Cancer Inst.* **95**, 154-159 (2003).

243. van der, A. D. L. *et al*. Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands). *Cancer Causes Control* **14**, 541-545 (2003).

244. Beckman, L. E. *et al*. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. *Carcinogenesis* **20**, 1231-1233 (1999).

245. Macdonald, G. A. *et al*. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. *Journal of Gastroenterology & Hepatology* **14**, 1188-1191 (1999).

246. Kervinen, K. *et al*. Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? *Gastroenterology* **110**, 1785-1790 (1996).

247. Butler, W. J., Ryan, P. & Roberts-Thomson, I. C. Metabolic genotypes and risk for colorectal cancer. *J Gastroenterol Hepatol* **16**, 631-635 (2001).

248. Watson, M. A. *et al*. Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis. *Clin. Sci. (Lond)* **104**, 537-545 (2003).

249. Slattery, M. L. *et al*. Associations between apoE genotype and colon and rectal cancer. *Carcinogenesis* **26**, 1422-1429 (2005).

250. Ewart-Toland, A. *et al*. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. *Carcinogenesis* **26**, 1368-1373 (2005).

251. Webb, E. L., Rudd, M. F. & Houlston, R. S. Case-control, kin-cohort and meta-analyses provide no support for STK15 F31I as a low penetrance colorectal cancer allele. *Br. J. Cancer* **95**, 1047-1049 (2006).

252. Phillips, L. S. *et al*. No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer. *World J. Gastroenterol.* **15**, 3771-3775 (2009).

253. Fidder, H. H. *et al*. Genetic analyses in consecutive israeli jewish colorectal cancer patients. *Am. J. Gastroenterol.* **100**, 1376-1380 (2005).

254. Cleary, S. P. *et al*. Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk. *Dis. Colon Rectum* **51**, 1467-73; discussion 1473-4 (2008).

255. Theodoratou, E. *et al*. Modification of the associations between lifestyle, dietary factors and colorectal cancer risk by APC variants. *Carcinogenesis* **29**, 1774-1780 (2008).

256. Popat, S. *et al*. Prevalence of the APC E1317Q variant in colorectal cancer patients. *Cancer Lett.* **149**, 203-206 (2000).

257. Rozek, L. S., Rennert, G. & Gruber, S. B. APC E1317Q is not associated with Colorectal Cancer in a population-based case-control study in Northern Israel. *Cancer Epidemiol. Biomarkers Prev.* **15**, 2325-2327 (2006).

258. Hahnloser, D. *et al*. The APC E1317Q variant in adenomatous polyps and colorectal cancers. *Cancer Epidemiol. Biomarkers Prev.* **12**, 1023-1028 (2003).

259. Menendez, M. *et al*. Colorectal cancer risk and the APC D1822V variant. *International Journal of Cancer* **112**, 161-163 (2004).

260. Tranah, G. J., Giovannucci, E., Ma, J., Fuchs, C. & Hunter, D. J. APC Asp1822Val and Gly2502Ser polymorphisms and risk of colorectal cancer and adenoma. *Cancer Epidemiol. Biomarkers Prev.* **14**, 863-870 (2005).

261. Guerreiro, C. S. *et al*. The D1822V APC polymorphism interacts with fat, calcium, and fiber intakes in modulating the risk of colorectal cancer in Portuguese persons. *Am. J. Clin. Nutr.* **85**, 1592-1597 (2007).

262. Slattery, M. L. *et al*. A molecular variant of the APC gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer. *Cancer Res.* **61**, 1000-1004 (2001).

263. Strul, H. *et al*. The I1307K adenomatous polyposis coli gene variant does not contribute in the assessment of the risk for colorectal cancer in Ashkenazi Jews. *Cancer Epidemiol. Biomarkers Prev.* **12**, 1012-1015 (2003).

264. Laken, S. J. *et al*. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. *Nat. Genet.* **17**, 79-83 (1997).

265. Starinsky, S. *et al*. Genotype phenotype correlations in Israeli colorectal cancer patients. *Int. J. Cancer* **114**, 58-73 (2005).

266. Samowitz, W. S. *et al*. The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. *Genes Chromosomes Cancer* **47**, 835-844 (2008).

267. Tulupova, E. *et al*. Do polymorphisms and haplotypes of mismatch repair genes modulate risk of sporadic colorectal cancer?. *Mutat. Res.* **648**, 40-45 (2008).

268. Raptis, S. *et al*. MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. *J. Natl. Cancer Inst.* **99**, 463-474 (2007).

269. Koessler, T. *et al*. Common variants in mismatch repair genes and risk of colorectal cancer. *Gut* **57**, 1097-1101 (2008).

270. Allan, J. M. *et al*. MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. *Int. J. Cancer* **123**, 2456-2459 (2008).

271. Berndt, S. I. *et al*. Mismatch repair polymorphisms and the risk of colorectal cancer. *Int. J. Cancer* **120**, 1548-1554 (2007).

272. Nejda, N. *et al*. A MLH1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer. *Cancer Genet. Cytogenet.* **193**, 71-77 (2009).

273. Mei, Q. *et al*. Single-nucleotide polymorphisms of mismatch repair genes in healthy Chinese individuals and sporadic colorectal cancer patients. *Cancer Genet. Cytogenet.* **171**, 17-23 (2006).

274. Kim, J. C. *et al*. Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. *Fam. Cancer.* **3**, 129-137 (2004).

275. Christensen, L. L. *et al*. The association between genetic variants in hMLH1 and hMSH2 and the development of sporadic colorectal cancer in the Danish population. *BMC Med. Genet.* **9**, 52 (2008).

276. Tao, W. P., Hu, S., Feng, J. P. & Xie, Y. S. [Association of MLH1 gene 415G/C polymorphism with colorectal cancer in Chinese]. *Chung Hua. I. Hsueh I. Chuan Hsueh Tsa. Chih.* **26**, 314-317 (2009).

277. Goessl, C. *et al*. An intronic germline transition in the HNPCC gene hMSH2 is associated with sporadic colorectal cancer. *Eur. J. Cancer* **33**, 1869-1874 (1997).

278. Campbell, P. T. *et al*. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. *Gut* **58**, 661-667 (2009).

279. Curtin, K. *et al*. MSH6 G39E polymorphism and CpG island methylator phenotype in colon cancer. *Mol. Carcinog.* **48**, 989-994 (2009).

280. Nisa, H. *et al*. Cigarette smoking, genetic polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. *BMC Cancer* **10**, 274 (2010).

281. Little, J. *et al*. Colorectal cancer and genetic polymorphisms of CYP1A1, GSTM1 and GSTT1: a case-control study in the Grampian region of Scotland. *International Journal of Cancer* **119**, 2155-2164 (2006).

282. Chen, K. *et al*. A case control study on the association between genetic polymorphisms of metabolic enzymes and the risk of colerectal cancer. *Zhonghua Liu Xing Bing Xue Za Zhi* **26**, 659-664 (2005).

283. Slattery, M. L. *et al*. CYP1A1, cigarette smoking, and colon and rectal cancer. *American Journal of Epidemiology* **160**, 842-852 (2004).

284. Cotterchio, M. *et al*. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. *Cancer Epidemiol. Biomarkers Prev.* **17**, 3098-3107 (2008).

285. Kiss, I. *et al*. Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-tranferase M1 enzymes. *Anticancer Res.* **20**, 519-522 (2000).

286. Kobayashi, M. *et al*. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of colorectal cancer: a hospital-based case-control study in Japan. *Scand. J. Gastroenterol.* **44**, 952-959 (2009).

287. Pereira Serafim, P. V., Cotrim Guerreiro da Silva, I. D. & Manoukias Forones, N. Relationship between genetic polymorphism of CYP1A1 at codon 462 (Ile462Val) in colorectal cancer. *Int. J. Biol. Markers* **23**, 18-23 (2008).

288. Kiss, I. *et al*. Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. *Anticancer Res.* **27**, 2931-2937 (2007).

289. Bethke, L. *et al*. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. *BMC Cancer* **7**, 123 (2007).

290. Saebo, M. *et al*. CYP1A2 164 A-->C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas. *Anticancer Res.* **28**, 2289-2295 (2008).

291. Kury, S. *et al*. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. *Cancer Epidemiol. Biomarkers Prev.* **16**, 1460-1467 (2007).

292. Bae, S. Y. *et al*. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. *Cancer. Sci.* **97**, 774-779 (2006).

293. Chen, K. *et al*. A case-control study on the association between genetic polymorphisms of metabolic enzymes and the risk of colorectal cancer]. *Zhonghua Liu Xing Bing Xue Za Zhi* **26**, 659-664 (2005).

294. Tamer, L. *et al*. CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma. *Int. J. Gastrointest. Cancer*. **37**, 1-5 (2006).

295. Martinez, C. *et al*. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. *Carcinogenesis* **22**, 1323-1326 (2001).

296. Liao, L. H. *et al*. The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. *Clin. Chim. Acta* **380**, 191-196 (2007).

297. Yu, W. P. *et al*. Genetic polymorphism in cytochrome P450 2E1, salted food and colorectal cancer susceptibility: a case-control study. *Zhonghua Yu Fang Yi Xue Za Zhi* **38**, 162-166 (2004).

298. Morita, M. *et al*. Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. *Cancer Epidemiol. Biomarkers Prev.* **18**, 235-241 (2009).

299. Gao, C. M. *et al*. CYP2E1 Rsa I polymorphism impacts on risk of colorectal cancer association with smoking and alcohol drinking. *World J. Gastroenterol.* **13**, 5725-5730 (2007).

300. Le Marchand, L., Donlon, T., Seifried, A. & Wilkens, L. R. Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. *Cancer Epidemiol. Biomarkers Prev.* **11**, 1019-1024 (2002).

301. Petrova, D. T. *et al*. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. *Onkologie* **30**, 559-563 (2007).

302. Hagiwara, T. *et al*. Genetic polymorphism in cytochrome P450 7A1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. *Cancer Res.* **65**, 2979-2982 (2005).

303. Sweeney, C., Coles, B. F., Nowell, S., Lang, N. P. & Kadlubar, F. F. Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer. *Toxicology* **181-182**, 83-87 (2002).

304. Martinez, C. *et al*. Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. *Pharmacogenomics* **7**, 711-718 (2006).

305. van der Logt, E. M. *et al*. Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. *Carcinogenesis* **25**, 2407-2415 (2004).

306. Economopoulos, K. P. & Sergentanis, T. N. GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. *Eur. J. Cancer* **46**, 1617-1631 (2010).

307. Yeh, C. C. *et al*. Protein carbonyl levels, glutathione S-transferase polymorphisms and risk of colorectal cancer. *Carcinogenesis* **31**, 228-233 (2010).

308. Yang, G. *et al*. Isothiocyanate exposure, glutathione S-transferase polymorphisms, and colorectal cancer risk. *Am. J. Clin. Nutr.* **91**, 704-711 (2010).

309. Piao, J. M. *et al*. Glutathione-S-transferase (GSTM1, GSTT1) and the risk of gastrointestinal cancer in a Korean population. *World J. Gastroenterol.* **15**, 5716-5721 (2009).

310. Epplein, M. *et al*. Urinary isothiocyanates; glutathione S-transferase M1, T1, and P1 polymorphisms; and risk of colorectal cancer: the Multiethnic Cohort Study. *Cancer Epidemiol. Biomarkers Prev.* **18**, 314-320 (2009).

311. Probst-Hensch, N. M. *et al*. The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese Health Study. *Carcinogenesis* **27**, 2475-2482 (2006).

312. Ates, N. A. *et al*. Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. *Biochem. Genet.* **43**, 149-163 (2005).

313. Yeh, C. -., Hsieh, L. -., Chang-Chieh, C. R., Tang, R. & Sung, F. -. Vegetable/fruit, smoking, glutathione S-transferase polymorphisms and risk for colorectal cancer in Taiwan. *World Journal of Gastroenterology* **11**, 1473-1480 (2005).

314. Loktionov, A. *et al*. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. *Carcinogenesis* **22**, 1053-1060 (2001).

315. Huang, K. *et al*. GSTM1 and GSTT1 polymorphisms, cigarette smoking, and risk of colon cancer: a population-based case-control study in North Carolina (United States). *Cancer Causes & Control* **17**, 385-394 (2006).

316. Fan, C. H. *et al*. Association between genetic polymorphisms of metabolic enzymes and susceptibility of colorectal cancer. *Zhonghua Yu Fang Yi Xue Za Zhi* **40**, 13-17 (2006).

317. Nascimento, H. *et al*. Possible influence of glutathione S-transferase GSTT1 null genotype on age of onset of sporadic colorectal adenocarcinoma. *Dis. Colon Rectum* **46**, 510-515 (2003).

318. Zhu, Y., Deng, C., Zhang, Y., Zhou, X. & He, X. [The relationship between GSTM1, GSTT1 gene polymorphisms and susceptibility to sporadic colorectal adenocarcinoma]. *Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine* **41**, 538-540 (2002).

319. Gertig, D. M. *et al*. Glutathione S-transferase GSTM1 and GSTT1 polymorphisms and colorectal cancer risk: a prospective study. *Cancer Epidemiology, Biomarkers & Prevention* **7**, 1001-1005 (1998).

320. Skjelbred, C. F. *et al*. Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. *BMC Cancer* **7**, 228 (2007).

321. Tiemersma, E. W. *et al*. Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: results from a Dutch prospective study. *Cancer Causes Control* **13**, 383-393 (2002).

322. Zhong, S., Wyllie, A. H., Barnes, D., Wolf, C. R. & Spurr, N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. *Carcinogenesis* **14**, 1821-1824 (1993).

323. Kampman, E. *et al*. Meat consumption, genetic susceptibility, and colon cancer risk: a United States multicenter case-control study. *Cancer Epidemiology, Biomarkers & Prevention* **8**, 15-24 (1999).

324. Slattery, M. L. *et al*. Western diet, family history of colorectal cancer, NAT2, GSTM-1 and risk of colon cancer. *Cancer Causes Control* **11**, 1-8 (2000).

325. Seow, A. *et al*. Dietary isothiocyanates, glutathione S-transferase polymorphisms and colorectal cancer risk in the Singapore Chinese Health Study. *Carcinogenesis* **23**, 2055-2061 (2002).

326. Deakin, M. *et al*. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. *Carcinogenesis* **17**, 881-884 (1996).

327. van der Hel, O. L. *et al*. No modifying effect of NAT1, GSTM1, and GSTT1 on the relation between smoking and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* **12**, 681-682 (2003).

328. Kiss, I. *et al*. Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer. *Anticancer Res.* **24**, 3965-3970 (2004).

329. Chenevix-Trench, G., Young, J., Coggan, M. & Board, P. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. *Carcinogenesis* **16**, 1655-1657 (1995).

330. Lee, E. *et al*. Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1, GSTT1, NAT1 and NAT2. *J. Toxicol. Sci.* **23**, 140-142 (1998).

331. Yoshioka, M. *et al*. Glutathione S-transferase (GST) M1, T1, P1, N-acetyltransferase (NAT) 1 and 2 genetic polymorphisms and susceptibility to colorectal cancer. *Sangyo Ika Daigaku Zasshi (Journal of University of Occupational, Environmental Health)* **21**, 133-147 (1999).

332. Matakova, T. *et al*. Polymorphisms of biotransforming enzymes (GSTs) and their association with colorectal cancer in the Slovak population. *Neoplasma* **56**, 422-427 (2009).

333. Slattery, M. L., Edwards, S., Curtin, K., Schaffer, D. & Neuhausen, S. Associations between smoking, passive smoking, GSTM-1, NAT2, and rectal cancer. *Cancer Epidemiology, Biomarkers & Prevention* **12**, 882-889 (2003).

334. Welfare, M., Adeokun, A. M., Bassendine, M. F. & Daly, A. K. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. *Cancer Epidemiol Biomarkers Prev* **8**, 289-292 (1999).

335. Csejtei, A. *et al*. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. *Anticancer Res.* **28**, 1917-1922 (2008).

336. Sgambato, A. *et al*. Glutathione S-Transferase (GST) polymorphisms as risk factors for cancer in a highly homogeneous population from Southern Italy. *Anticancer Res.* **22**, 3647-3652 (2002).

337. Laso, N. *et al*. Glutathione s-transferase (GSTM1 and GSTT1)-dependent risk for colorectal cancer. *Anticancer Res.* **22**, 3399-3403 (2002).

338. Katoh, T. *et al*. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. *Carcinogenesis* **17**, 1855-1859 (1996).

339. Sun, X. F. *et al*. Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients' survival. *World J. Gastroenterol.* **11**, 6875-6879 (2005).

340. Harris, M. J., Coggan, M., Langton, L., Board, P. G. & Wilson, S. R. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. *Pharmacogenetics* **8**, 27-31 (1998).

341. Katoh, T. *et al*. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. *Pharmacogenetics* **9**, 165-169 (1999).

342. Rajagopal, R. *et al*. Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer. *Carcinogenesis* **26**, 2157-2163 (2005).

343. Katoh, T. *et al*. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. *International Journal of Cancer* **85**, 46-49 (2000).

344. Chen, J. *et al*. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. *Cancer Res.* **58**, 3307-3311 (1998).

345. Jass, J. R., Allison, L. J. & Edgar, S. G. Distribution of sialosyl Tn and Tn antigens within normal and malignant colorectal epithelium. *J. Pathol.* **176**, 143-149 (1995).

346. Mahid, S. S. *et al*. Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma. *BMC Medical Genetics* **8**, 28 (2007).

347. Roemer, H. C. *et al*. N-acetyltransferase 1 in colon and rectal cancer cases from an industrialized area. *J. Toxicol. Environ. Health A* **71**, 902-905 (2008).

348. Butler, L. M. *et al*. Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study. *Mutat. Res.* **638**, 162-174 (2008).

349. Lilla, C. *et al*. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. *Cancer Epidemiol. Biomarkers Prev.* **15**, 99-107 (2006).

350. Le Marchand, L. *et al*. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. *Cancer Epidemiol. Biomarkers Prev.* **10**, 1259-1266 (2001).

351. Sorensen, M. *et al*. Prospective study of NAT1 and NAT2 polymorphisms, tobacco smoking and meat consumption and risk of colorectal cancer. *Cancer Lett.* **266**, 186-193 (2008).

352. Slattery, M. L. *et al*. NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. *Cancer Epidemiol Biomarkers Prev* **7**, 1079-1084 (1998).

353. Hubbard, A. L. *et al*. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. *Gut* **41**, 229-234 (1997).

354. Lee, E. J., Zhao, B. & Seow-Choen, F. Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population. *Pharmacogenetics* **8**, 513-517 (1998).

355. Gil, J. P. & Lechner, M. C. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. *Carcinogenesis* **19**, 37-41 (1998).

356. Huang, C. C. *et al*. NAT2 fast acetylator genotype is associated with an increased risk of colorectal cancer in Taiwan. *Dis. Colon Rectum* **50**, 981-989 (2007).

357. Chan, A. T. *et al*. Prospective study of N-acetyltransferase-2 genotypes, meat intake, smoking and risk of colorectal cancer. *Int. J. Cancer* **115**, 648-652 (2005).

358. Agundez, J. A. G. *et al*. N-acetyltransferase 2 (NAT2) genotype and colorectal carcinoma: risk variability according to tumour site? *Scand. J. Gastroenterol.* **35**, 1087-1091 (2000).

359. Bell, D. A. *et al*. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. *Cancer Res.* **55**, 3537-3542 (1995).

360. Shibuta, K. *et al*. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. *Cancer* **74**, 3108-3112 (1994).

361. Hamajima, N. *et al*. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. *Int. J. Clin. Oncol.* **7**, 103-108 (2002).

362. Harth, V. *et al*. NAD(P)H quinone oxidoreductase 1 codon 609 polymorphism and its association to colorectal cancer. *Arch. Toxicol.* **73**, 528-531 (1999).

363. Sachse, C. *et al*. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. *Carcinogenesis* **23**, 1839-1849 (2002).

364. Van Der Logt, E. M. *et al*. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. *Anticancer Res.* **25**, 1465-1470 (2005).

365. Lafuente, M. J. *et al*. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. *Carcinogenesis* **21**, 1813-1819 (2000).

366. Begleiter, A., Hewitt, D., Maksymiuk, A. W., Ross, D. A. & Bird, R. P. A NAD(P)H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. *Cancer Epidemiology, Biomarkers & Prevention* **15**, 2422-2426 (2006).

367. Mitrou, P. *et al*. NQO1 and mEH exon 4 (mEH4) gene polymorphisms, smoking and colorectal cancer risk. *IARC Sci. Publ.* **156**, 495-497 (2002).

368. Economopoulos, K. P., Sergentanis, T. N., Zagouri, F. & Zografos, G. C. Association between p53 Arg72Pro polymorphism and colorectal cancer risk: a meta-analysis. *Onkologie* **33**, 666-674 (2010).

369. Hu, Z. *et al*. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. *Carcinogenesis* **31**, 643-647 (2010).

370. Fang, F., Yu, X. J., Yu, L. & Yao, L. MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. *Med. Oncol.* (2010).

371. Flugge, J. *et al*. Vitamin D receptor haplotypes protect against development of colorectal cancer. *Eur. J. Clin. Pharmacol.* **63**, 997-1005 (2007).

372. Jenab, M. *et al*. Vitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in European populations. *Cancer Epidemiol. Biomarkers Prev.* **18**, 2485-2491 (2009).

373. Li, C. *et al*. Vitamin D receptor gene polymorphisms and the risk of colorectal cancer in a Chinese population. *Dig. Dis. Sci.* **54**, 634-639 (2009).

374. Murtaugh, M. A. *et al*. Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. *Nutr. Cancer* **55**, 35-43 (2006).

375. Ochs-Balcom, H. M. *et al*. Association of vitamin D receptor gene variants, adiposity and colon cancer. *Carcinogenesis* **29**, 1788-1793 (2008).

376. Theodoratou, E. *et al*. Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a FokI variant supports a chemoprotective action of Vitamin D intake mediated through VDR binding. *Int. J. Cancer* **123**, 2170-2179 (2008).

377. Park, K., Woo, M., Nam, J. & Kim, J. C. Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. *Cancer Lett.* **237**, 199-206 (2006).

378. Wong, H. L. *et al*. Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. *Carcinogenesis* **24**, 1091-1095 (2003).

379. Slattery, M. L. *et al*. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. *Cancer Epidemiology, Biomarkers & Prevention* **13**, 538-545 (2004).

380. Slatter, M. L., Yakumo, K., Hoffman, M. & Neuhausen, S. Variants of the VDR gene and risk of colon cancer (United States). *Cancer Causes Control* **12**, 359-364 (2001).

381. Flugge, J., Laschinski, G., Roots, I. & Krusekopf, S. Vitamin D receptor poly(A) microsatellite and colorectal cancer risk in Caucasians. *Int. J. Colorectal Dis.* **24**, 171-175 (2009).